THE FOUNDATION FOR AIDS RESEARCH: Form 990, tax year 2020

View the entire original 990 at ProPublica ↗

Organization: THE FOUNDATION FOR AIDS RESEARCH (EIN 13-3163817)
Tax period: 2020-10-01 to 2021-09-30
Filed: 2022-06-27
IRS object ID: 202241789349300334
Schema version: 2020v4.2
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule C
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule M
Schedule O

Return header ReturnHeader

Field	Value	IRS element (for citing)
Return	2022-06-27T12:50:24-05:00	ReturnTs
Tax Period End	2021-09-30	TaxPeriodEndDt

Preparer Firm PreparerFirmGrp

Field	Value	IRS element (for citing)
Preparer Firm EIN	366055558	PreparerFirmEIN

Preparer Firm Name PreparerFirmName

Field	Value	IRS element (for citing)
Business Name Line1	GRANT THORNTON LLP	BusinessNameLine1Txt

Preparer US Address PreparerUSAddress

Field	Value	IRS element (for citing)
Address Line1	757 THIRD AVE 3RD FLOOR	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	100172013	ZIPCd

Field	Value	IRS element (for citing)
Return Type	990	ReturnTypeCd
Tax Period Begin	2020-10-01	TaxPeriodBeginDt

Filer Filer

Field	Value	IRS element (for citing)
EIN	133163817	EIN

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	THE FOUNDATION FOR AIDS RESEARCH	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Business Name Control	FOUN	BusinessNameControlTxt
Phone	2128061600	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	100053908	ZIPCd

Business Officer BusinessOfficerGrp

Field	Value	IRS element (for citing)
Person	BRADLEY JENSEN	PersonNm
Person Title	ASST TREASURER	PersonTitleTxt
Phone	2128061600	PhoneNum
Signature	2022-06-27	SignatureDt
Discuss With Paid Preparer	Yes (1)	DiscussWithPaidPreparerInd

Signing Officer SigningOfficerGrp

Person Full Name PersonFullName

Field	Value	IRS element (for citing)
Person First	BRADLEY	PersonFirstNm
Person Last	JENSEN	PersonLastNm

Field	Value	IRS element (for citing)
SSN	XXX-XX-XXXX	SSN

Preparer Person PreparerPersonGrp

Field	Value	IRS element (for citing)
Preparer Person	SCOTT THOMPSETT	PreparerPersonNm
PTIN	P00741490	PTIN
Phone	2125990100	PhoneNum

Additional Filer Information AdditionalFilerInformation

Trusted Customer TrustedCustomerGrp

Field	Value	IRS element (for citing)
Trusted Customer	3	TrustedCustomerCd
Authentication Assurance Level	AAL1	AuthenticationAssuranceLevelCd
Identity Assurance Level	IAL1	IdentityAssuranceLevelCd

Field	Value	IRS element (for citing)
Tax	2020	TaxYr
Build TS	2022-09-23 18:48:47Z	BuildTS

Form 990 IRS990

Doing Business As Name DoingBusinessAsName

Field	Value	IRS element (for citing)
Business Name Line1	AIDS RESEARCH FOUNDATION OR AMFAR	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Principal Officer	KEVIN FROST	PrincipalOfficerNm

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FL	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	10005	ZIPCd

Field	Value	IRS element (for citing)
Gross Receipts	$44,118,603	GrossReceiptsAmt
Group Return For Affiliates	0	GroupReturnForAffiliatesInd
Organization501c3	Yes (X)	Organization501c3Ind
Website Address	WWW.AMFAR.ORG	WebsiteAddressTxt
Type Of Organization Corp	Yes (X)	TypeOfOrganizationCorpInd
Formation	1983	FormationYr
Legal Domicile State	NY	LegalDomicileStateCd
Activity Or Mission	AMFAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. (SEE SCHEDULE O).	ActivityOrMissionDesc
Voting Members Governing Body	17	VotingMembersGoverningBodyCnt
Voting Members Independent	17	VotingMembersIndependentCnt
Total Employee	79	TotalEmployeeCnt
Total Volunteers	0	TotalVolunteersCnt
Total Gross UBI	$0	TotalGrossUBIAmt
Net Unrelated Bus Txbl Incm	$0	NetUnrelatedBusTxblIncmAmt
PY Contributions Grants	$21,630,486	PYContributionsGrantsAmt
CY Contributions Grants	$28,196,461	CYContributionsGrantsAmt
PY Program Service Revenue	$0	PYProgramServiceRevenueAmt
CY Program Service Revenue	$0	CYProgramServiceRevenueAmt
PY Investment Income	$3,193,491	PYInvestmentIncomeAmt
CY Investment Income	$2,662,978	CYInvestmentIncomeAmt
PY Other Revenue	-$3,481,467	PYOtherRevenueAmt
CY Other Revenue	-$7,327,980	CYOtherRevenueAmt
PY Total Revenue	$21,342,510	PYTotalRevenueAmt
CY Total Revenue	$23,531,459	CYTotalRevenueAmt
PY Grants And Similar Paid	$5,897,226	PYGrantsAndSimilarPaidAmt
CY Grants And Similar Paid	$6,314,851	CYGrantsAndSimilarPaidAmt
PY Benefits Paid To Members	$0	PYBenefitsPaidToMembersAmt
CY Benefits Paid To Members	$0	CYBenefitsPaidToMembersAmt
PY Salaries Comp Emp Bnft Paid	$11,392,441	PYSalariesCompEmpBnftPaidAmt
CY Salaries Comp Emp Bnft Paid	$11,298,648	CYSalariesCompEmpBnftPaidAmt
PY Total Prof Fndrsng Expns	$469,617	PYTotalProfFndrsngExpnsAmt
CY Total Prof Fndrsng Expns	$428,334	CYTotalProfFndrsngExpnsAmt
CY Total Fundraising Expense	$4,953,774	CYTotalFundraisingExpenseAmt
PY Other Expenses	$11,082,612	PYOtherExpensesAmt
CY Other Expenses	$9,630,117	CYOtherExpensesAmt
PY Total Expenses	$28,841,896	PYTotalExpensesAmt
CY Total Expenses	$27,671,950	CYTotalExpensesAmt
PY Revenues Less Expenses	-$7,499,386	PYRevenuesLessExpensesAmt
CY Revenues Less Expenses	-$4,140,491	CYRevenuesLessExpensesAmt
Total Assets BOY	$54,739,518	TotalAssetsBOYAmt
Total Assets EOY	$55,843,595	TotalAssetsEOYAmt
Total Liabilities BOY	$13,093,624	TotalLiabilitiesBOYAmt
Total Liabilities EOY	$17,223,316	TotalLiabilitiesEOYAmt
Net Assets Or Fund Balances BOY	$41,645,894	NetAssetsOrFundBalancesBOYAmt
Net Assets Or Fund Balances EOY	$38,620,279	NetAssetsOrFundBalancesEOYAmt
Info In Schedule O Part III	Yes (X)	InfoInScheduleOPartIIIInd
Mission	SEE SCHEDULE O.	MissionDesc
Significant New Program Srvc	0	SignificantNewProgramSrvcInd
Significant Change	0	SignificantChangeInd
Expense	$10,905,654	ExpenseAmt
Grant	$4,260,993	GrantAmt
Revenue	$0	RevenueAmt
Desc	RESEARCH: AMFAR SUPPORTS RESEARCH PROJECTS THAT EXPLORE NOVEL APPROACHES TO SCIENTIFICALLY SOUND BUT UNTESTED HYPOTHESES IN ALL AREAS OF RESEARCH ON HIV/AIDS, FUNDING GOAL-ORIENTED STUDIES THAT OFTEN LACK THE PRELIMINARY DATA REQUIRED FOR SUPPORT FROM TRADITIONAL GRANT MAKERS. THE FOUNDATION PLAYS A VITAL ROLE IN HIV/AIDS RESEARCH, IDENTIFYING CRITICAL GAPS IN KNOWLEDGE AND PROVIDING ESSENTIAL SEED MONEY THAT ENABLES GRANTEES AND FELLOWS TO TEST THE MERITS OF NEW CONCEPTS OR TECHNOLOGIES THAT SUBSEQUENTLY CAN BE VALIDATED THROUGH LARGE-SCALE STUDIES, SUCH AS THOSE FUNDED BY THE U.S. NATIONAL INSTITUTES OF HEALTH. FOR FURTHER DETAILS, SEE SCHEDULE O. AMFAR FELLOWSHIPS ALLOW TALENTED YOUNG RESEARCHERS TO CONDUCT ORIGINAL INVESTIGATIONS UNDER THE GUIDANCE OF EXPERIENCED SCIENTISTS, HELPING TO ENSURE THE LONG-TERM VITALITY OF AIDS RESEARCH.NEW GRANTS AND FELLOWSHIPSGRANTS AND FELLOWSHIPS ARE AWARDED THROUGH A RIGOROUS PROCESS OF PEER REVIEW BY A TEAM OF INDEPENDENT HIV/AIDS EXPERTS DRAWN LARGELY FROM THE VOLUNTEER SCIENTISTS ON AMFAR'S SCIENTIFIC ADVISORY COMMITTEE. GUIDED BY ITS SCIENTIFIC ADVISORS AND WITH THE APPROVAL OF ITS BOARD OF TRUSTEES, AMFAR PURSUES A STRATEGIC RESEARCH PLAN THAT FOCUSES ON FINDING A CURE FOR HIV. AMFAR'S GRANTMAKING PROGRAM CONSISTS OF THE FOLLOWING TYPES OF GRANTS:MAGNET GRANTSUNITING DATA SCIENTISTS WITH HIV RESEARCHERS, THESE ONE-YEAR GRANTS OF UP TO $150,000 ARE HARNESSING ADVANCES IN MACHINE-LEARNING ALGORITHMS TO FIND PATTERNS IN DATASETS THAT MAY ADVANCE OUR SEARCH FOR A CURE.SYNERGY GRANTSTHESE GRANTS CAPITALIZE ON UNFORESEEN POSSIBILITIES FOR COLLABORATION AND ENABLE US TO ADD NEW STUDY ARMS ONTO EXISTING AMFAR GRANTS.TARGET GRANTSTHESE GRANTS FACILITATE BASIC AND PRECLINICAL BIOMEDICAL RESEARCH FINDINGS THAT PROVIDE THE FOUNDATION FOR NEW APPROACHES TO AN HIV CURE.MATHILDE KRIM FELLOWSHIPS IN BASIC BIOMEDICAL RESEARCHNAMED FOR AMFAR'S FOUNDING CHAIRMAN DR. MATHILDE KRIM, THIS FELLOWSHIP PROGRAM SUPPORTS PROMISING EARLY-CAREER SCIENTISTS ADVANCING INNOVATIVE SOLUTIONS TO HIV/AIDS. COUNTDOWN TO A CURE FOR AIDSIN 2015, AMFAR ANNOUNCED A MULTIMILLION-DOLLAR INVESTMENT STRATEGY TO SUPPORT ITS COUNTDOWN TO A CURE FOR AIDS (C2C) INITIATIVE, WHICH WAS AIMED AT DEVELOPING THE SCIENTIFIC BASIS FOR A CURE BY THE END OF 2020. ESTABLISHED WITH A $20 MILLION GRANT OVER FIVE YEARS TO THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE AMFAR INSTITUTE FOR HIV CURE RESEARCH WAS THE CORNERSTONE OF C2C. THE STRATEGY WAS DESIGNED TO PROVIDE SUPPORT TO ANY SCIENTIST OR TEAM OF INVESTIGATORS FOR ANY RESEARCH IDEA WITH THE POTENTIAL TO ADVANCE THE SEARCH FOR A CURE, AT ANY STAGE OF ITS DEVELOPMENT. SINCE LAUNCHING C2C, AMFAR HAS AWARDED 89 COUNTDOWN GRANTS TOTALING MORE THAN $50 MILLION TO SUPPORT RESEARCH CONDUCTED BY 307 SCIENTISTS WORKING AT 103 INSTITUTIONS IN 16 COUNTRIES.TARGET GRANTSIN NOVEMBER 2020 AMFAR AWARDED FUNDING TO A RESEARCHER EXPLORING AN HIV CURE APPROACH THAT HAS PREVIOUSLY SHOWN PROMISE IN CANCER THERAPY. VETERAN HIV RESEARCHER DR. JEROME ZACK, OF THE UNIVERSITY OF CALIFORNIA, LOS ANGELES, IS EMPLOYING A NEW INTERVENTION TO ATTEMPT TO RID THE BODY OF THE PERSISTENT RESERVOIR OF HIVTHE ULTIMATE BARRIER TO A CURE. DR. ZACK AND COLLEAGUES ARE USING NATURAL KILLER (NK) CELLS IN AN EFFORT TO ELIMINATE CELLS HARBORING RESERVOIR VIRUS FROM THE BODY. NK CELLS ARE THE FOOT SOLDIERS OF THE INNATE IMMUNE SYSTEM, DELIVERING AN IMMEDIATE AND POTENT COUNTERATTACK AGAINST INFECTIOUS AGENTS SUCH AS HIV.THESE CELLS CAN BE ADMINISTERED EITHER IN THEIR NATURALLY OCCURRING FORM, OR THEY CAN BE ENGINEERED AS CAR-NK CELLS TO ENHANCE THEIR ABILITY TO KILL THEIR TARGETS. TO COMPARE THE ABILITY OF UNALTERED AND CAR-NK CELLS TO AFFECT THE REBOUND OF VIRUS WHEN ANTIRETROVIRAL THERAPY IS WITHDRAWN, THE RESEARCHERS ARE EMPLOYING SEVERAL NOVEL TECHNOLOGIES DEVELOPED BY DR. ZACK. THESE INCLUDE THE INSERTION OF A BARCODE INTO VIRUSES SO THAT THE FATE OF EACH INDIVIDUAL VIRUS CAN BE TRACKED, AND USE OF A LATENCY REVERSING AGENT DEVELOPED IN HIS LAB.IN JUNE 2021 AMFAR AWARDED APPROXIMATELY $600,000 IN NEW FUNDING TO RESEARCHERS PIONEERING GENE THERAPY APPROACHES TO TARGET AND ELIMINATE THE HIV RESERVOIR WITH FAR GREATER SPECIFICITY THAN IS CURRENTLY POSSIBLE. DR. TODD ALLEN OF THE RAGON INSTITUTE OF MGH, MIT AND HARVARD, AND COLLEAGUES, HAVE IDENTIFIED A GROUP OF ANTIBODIES THEY HAVE CALLED BROADLY FUNCTIONAL ANTIBODIES (BFABS). THESE BFABS ARE ADEPT AT BINDING TO INFECTED CELLS AND FLAGGING THEM FOR DESTRUCTION BY OTHER COMPONENTS OF THE IMMUNE SYSTEM SUCH AS NATURAL KILLER (NK) CELLS. DR. ALLEN AND HIS TEAM AIM TO TEST THE BFABS ALONE AND IN COMBINATION WITH GENETICALLY ENGINEERED CAR T CELLS WITH ENHANCED ABILITY TO KILL CELLS INFECTED BY HIV THAT HIS TEAM HAS ALREADY DESIGNED. THE INTERVENTIONS WILL BE TESTED IN HIV-INFECTED MICE POPULATED WITH HUMAN IMMUNE CELLS AND WILL TARGET ONLY THOSE CELLS THAT ARE INFECTED WITH HIV.CAR T CELLS HAVE PROVEN HIGHLY EFFECTIVE AGAINST CERTAIN BLOOD CANCERS, BUT LESS SO AGAINST HIVPARTLY BECAUSE THEY ARE SUSCEPTIBLE TO INFECTION AND DESTRUCTION BY THE VIRUS. THE IMMENSE GENETIC VARIABILITY AMONG VIRUSES EVEN WITHIN AN INDIVIDUAL WITH HIV ALSO PRESENTS A FORMIDABLE CHALLENGE. A TEAM LED BY DR. ANASTASIOS KARADIMITRIS OF IMPERIAL COLLEGE, LONDON, PLANS TO ADDRESS BOTH ISSUES BY USING CELLS THAT COMBINE THE CHARACTERISTICS OF NATURALLY OCCURRING NK CELLS AND T CELLS AS THE BASIS FOR THEIR CAR CELL THERAPY. THESE INVARIANT (I) NKT CELLS DO NOT CARRY THE CD4 PROTEIN ON THEIR SURFACE AND THUS ARE RESISTANT TO HIV INFECTION. TO ADDRESS GENETIC BREADTH, THE RESEARCHERS WILL USE COMBINATIONS OF UP TO THREE TARGETING STRATEGIES. UNLIKE CONVENTIONAL T CELLS, THERE IS LITTLE VARIABILITY IN INKT CELLS AMONG THE HUMAN POPULATION, SO IT MAY BE POSSIBLE TO DESIGN "OFF THE SHELF" CAR-INKT CELLS THAT WOULD WORK IN MOST PEOPLE WITH HIV, RATHER THAN HAVING TO MANUFACTURE CAR T CELLS FROM EACH INDIVIDUAL PATIENT. CRISPR/CAS GENE-EDITING TECHNOLOGY HAS SHOWN BREAKTHROUGH POTENTIAL FOR TREATING A RANGE OF MEDICAL CONDITIONS. IN THE FIELD OF HIV CURE RESEARCH, THE PROSPECT OF BEING ABLE TO EXCISE THE VIRUS WHEREVER IT HAS INSERTED ITSELF INTO HOST DNA IS A TANTALIZING ONE. BUT ITS DELIVERY REMAINS A CHALLENGE. ACROSS THE GENOME THERE ARE VERY TIGHTLY WOUND REGIONS THAT LIMIT ACCESS TO THE DNA AND HAVE PROVEN DIFFICULT FOR CRISPR/CAS TO PENETRATE EFFECTIVELY. RECENT EVIDENCE SHOWS THAT HIV SOMETIMES INTEGRATES INTO THESE "GENE DESERTS." DR. JORI SYMONS OF UNIVERSITY MEDICAL CENTER UTRECHT, AND COLLEAGUES, PLAN TO TEST WHETHER THIS EXPLAINS THE RESISTANCE OF SOME VIRUSES TO EXCISION BY CRISPR/CAS. THEY AIM TO INCREASE THE GENE-EDITING TOOL'S EFFECTIVENESS WITH DRUGS THAT OPEN UP AND EXPOSE THE DNA.	Desc

Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp

Field	Value	IRS element (for citing)
Expense	$4,446,646	ExpenseAmt
Grant	$1,863,626	GrantAmt
Revenue	$0	RevenueAmt
Desc	TREAT ASIA: AMFAR'S TREAT ASIA (THERAPEUTICS RESEARCH, EDUCATION, AND AIDS TRAINING IN ASIA) PROGRAM IS A NETWORK OF HOSPITALS, CLINICS, AND RESEARCH INSTITUTIONS WORKING WITH CIVIL SOCIETY TO ENSURE THE SAFE AND EFFECTIVE DELIVERY OF TREATMENTS FOR HIV AND ITS CO-INFECTIONS TO ADULTS AND CHILDREN ACROSS THE ASIA-PACIFIC THROUGH RESEARCH, EDUCATION, AND ADVOCACY OF EVIDENCE-BASED HIV-RELATED POLICIES. THE TREAT ASIA NETWORK ENCOMPASSES 21 ADULT AND 20 PEDIATRIC SITES THROUGHOUT THE REGION, WHICH COLLABORATE ON A VARIETY OF PROJECTS. FOR FURTHER DETAILS, SEE SCHEDULE O. TREAT ASIA SCIENTISTS PRODUCED 28 PUBLICATIONS IN PEER-REVIEWED MEDICAL JOURNALS IN FY2021. INTERNATIONAL AIDS DATABASETREAT ASIA MANAGES THE ASIA-PACIFIC SECTION OF THE INTERNATIONAL EPIDEMIOLOGY DATABASES TO EVALUATE AIDS (IEDEA), A GLOBAL COLLABORATION ESTABLISHED BY THE U.S. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES. TREAT ASIA HIV OBSERVATIONAL DATABASE (TAHOD)TREAT ASIA PIONEERED THE REGION'S FIRST ADULT OBSERVATIONAL DATABASE FOR HIV/AIDS, WHICH NOW INCLUDES ANONYMOUS DATA FROM MORE THAN 10,000 PATIENTS AT 21 CLINICAL SITES IN 12 COUNTRIES. THE INFORMATION GATHERED IN THE DATABASE INFORMS THE DEVELOPMENT OF MORE EFFECTIVE RESEARCH AND TREATMENT PROGRAMS AND HELPS DEFINE TREATMENT STANDARDS SPECIFIC TO HIV/AIDS IN ASIA. TAHOD LOW-INTENSITY TRANSFER LAUNCHED IN 2014, TAHOD LOW-INTENSITY TRANSFER (TAHOD-LITE) CONTAINS DATA FROM OVER 51,000 HIV-POSITIVE PATIENTS ACROSS 11 TREAT ASIA NETWORK SITES. AS AN EXTENSION OF TAHOD, TAHOD-LITE AIMS TO INCREASE THE SCOPE OF ADULT DATA COLLECTION BY GATHERING A SUBSET OF CORE VARIABLES FROM THE ENTIRE COHORT OF HIV-INFECTED PATIENTS WHO HAVE SOUGHT CARE AT SELECTED TAHOD SITES. TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE THE TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TAPHOD) IS A REGIONAL PEDIATRIC HIV STUDY SET UP BY TREAT ASIA IN 2006. IT WAS MODELED AFTER THE ADULT DATABASE AND INCLUDES DATA FROM MORE THAN 7,400 CHILDREN AND ADOLESCENTS AT 17 CLINICAL SITES IN CAMBODIA, INDIA, INDONESIA, MALAYSIA, THAILAND, AND VIETNAM.TAHOD AND TAPHOD ANNUAL MEETINGSIN NOVEMBER 2020 BOTH THE TAHOD AND TAPHOD STEERING COMMITTEES HELD THEIR ANNUAL MEETINGS, WITH THAILAND-BASED INVESTIGATORS ATTENDING IN BANGKOK AND REGIONAL INVESTIGATORS JOINING VIRTUALLY. ATTENDED BY INVESTIGATORS AND STUDY COORDINATORS, THE MEETINGS INCLUDED UPDATES AND DISCUSSIONS ON TAHOD AND TAPHOD DATA, PROPOSED ANALYSES, AND ONGOING AND NEW SUB-STUDIES. INTEGRATING HIV, MENTAL HEALTH, AND IMPLEMENTATION SCIENCE RESEARCHIN 2019, THE U.S. NATIONAL INSTITUTES OF HEALTH AWARDED A FIVE-YEAR, $1.4 MILLION GRANT TO TREAT ASIA AND COLUMBIA UNIVERSITY TO ESTABLISH AN INNOVATIVE PLATFORM FOR INTEGRATING HIV, MENTAL HEALTH, AND IMPLEMENTATION SCIENCE RESEARCH IN THE ASIA-PACIFIC REGION. THE OBJECTIVE OF THE CHIMERA PROGRAM (CAPACITY DEVELOPMENT FOR HIV AND MENTAL HEALTH RESEARCH IN ASIA) IS TO ADDRESS THE DUAL AND INTERLINKED BURDENS OF HIV AND MENTAL HEALTH. CO-LED BY PRINCIPAL INVESTIGATORS DR. ANNETTE SOHN, AMFAR VICE PRESIDENT AND DIRECTOR OF TREAT ASIA, AND DR. MILTON WAINBERG, PROFESSOR OF CLINICAL PSYCHIATRY AT COLUMBIA UNIVERSITY AND THE NEW YORK STATE PSYCHIATRIC INSTITUTE, THE PROGRAM AIMS TO BUILD A TEAM WITHIN THE ASIA-PACIFIC WITH THE CAPACITY TO LEAD REGIONAL HIV-MENTAL HEALTH-IMPLEMENTATION SCIENCE RESEARCH THAT WILL INFORM PUBLIC HEALTH POLICY AND IMPROVE THE QUALITY OF CLINICAL CARE FOR PEOPLE LIVING WITH HIV. THE PROGRAM IS NESTED WITHIN THE IEDEA (SEE ABOVE) ASIA-PACIFIC REGIONAL RESEARCH NETWORK THAT TREAT ASIA DIRECTS. CHIMERA CREATES THE OPPORTUNITY TO BRING TOGETHER STELLAR TRAINING FACULTY FROM ACADEMIC CENTERS AND PUBLIC HEALTH AND DEVELOPMENT AGENCIES WITHIN THE REGION AND ACROSS THE WORLD, AND WILL BUILD ON EXISTING NIH-FUNDED MENTAL HEALTH RESEARCH BEING CONDUCTED THROUGH IEDEA ASIA-PACIFIC.IN DECEMBER 2020, A FINAL WORKSHOP FOR THE FIRST CLASS OF CHIMERA FELLOWS WAS HELD REMOTELY, COVERING IMPLEMENTATION RESEARCH METHODS, RESPONSIBLE CONDUCT OF RESEARCH, POLICY DEVELOPMENT, STIGMA, COMMUNITY PARTICIPATION IN RESEARCH, AND SCIENTIFIC WRITING. SIX OF EIGHT CLASS I FELLOWS BEGAN IMPLEMENTATION OF THEIR PILOT RESEARCH STUDIES IN 2021. A SECOND CLASS OF EIGHT FELLOWS ATTENDED PROGRAM ORIENTATION IN APRIL 2021. COVID-19 TREAT ASIA IS COLLABORATING WITH THE INSTITUTE OF HIV RESEARCH AND INNOVATION (IHRI), THAI RED CROSS AIDS RESEARCH CENTER (TRC-ARC) LABORATORY, AND THE NIH VACCINE RESEARCH CENTER (VRC) TO CONDUCT SARS-COV-2 SEROLOGIC ASSAYS OF THAI ADULTS TAKING AND NOT TAKING ANTIRETROVIRAL DRUGS FOR PRE-EXPOSURE PROPHYLAXIS AND TREATMENT OF HIV. IN SEPTEMBER 2020, MORE THAN 1,800 SAMPLES WERE SENT TO THE NATIONAL INSTITUTES OF HEALTH. IN 2021 THE NIH VRC PROPOSED AN EXPANSION OF THE STUDY COLLABORATION TO FOLLOW LONGITUDINAL SEROLOGIC PATTERNS AND ASSESS FOR INFECTIONS WITH OTHER VIRAL PATHOGENS. A DRAFT PROTOCOL WAS DEVELOPED AND SHARED WITH THE WORKING GROUP IN SEPTEMBER 2021. IN 2021 TREAT ASIA LAUNCHED A NEW WEBSITEWWW.COVID19ASIAINFO.ORGAN IMPORTANT NEW SOURCE OF INFORMATION ON COVID VACCINES AND THERAPEUTICS RELEVANT TO THE ASIA-PACIFIC REGION. THROUGHOUT THE YEAR, TREAT ASIA CONTINUED TO PARTICIPATE IN MEETINGS HELD VIRTUALLY WITH ORGANIZATIONS AND COMMUNITY MEMBERS FROM COUNTRIES THROUGHOUT THE ASIA-PACIFIC REGION TO NAVIGATE THE IMPACTS OF COVID-19 ON CRITICAL HIV AND HEPATITIS SERVICES AND INITIATIVES.HELPING ADOLESCENTS TRANSITION TO ADULT CAREMORE THAN ONE IN FOUR NEW HIV INFECTIONS IN THE ASIA-PACIFIC OCCUR IN YOUNG PEOPLE AGED 1524. CONTINUING ITS COMMITMENT TO HELPING ADOLESCENTS TRANSITION TO ADULT CARE, IN 2019 TREAT ASIA INITIATED PLANS FOR A STUDY OF ADOLESCENTS AND YOUNG ADULTS LIVING WITH HIV. A TOTAL OF AT LEAST 75 HIV-DISCLOSED ADOLESCENTS WITH HIV WILL BE ENROLLED FROM THREE PARTICIPATING SITES IN THAILAND AND THE PHILIPPINES FOR INITIAL AND 12-MONTH FOLLOW-UP ASSESSMENTS. CRITICAL OUTCOMES INCLUDING VIRAL SUPPRESSION, TREATMENT ADHERENCE, PREGNANCY, AND MORTALITY WILL BE ASSESSED. ENROLLMENT BEGAN IN 2021. PUBLICATIONSIN 2021 TREAT ASIA CONTINUED TO PUBLISH LAY-LANGUAGE ARTICLES ON HIV/AIDS RESEARCH, POLICY, AND COMMUNITY ISSUES FACING THE ASIA-PACIFIC AS A WHOLE. THE ARTICLES AND EDUCATIONAL PIECES APPEAR ON TREAT ASIA'S WEBSITE, WWW.TREATASIA.ORG.IAS 2021 AND OTHER CONFERENCESTREAT ASIA STAFF AND NETWORK INVESTIGATORS ATTENDED AND PRESENTED AT SEVERAL REGIONAL AND INTERNATIONAL CONFERENCES ON HIV-RELATED ISSUES. TREAT ASIA HAD A STRONG PRESENCE AT THE 11TH IAS CONFERENCE ON HIV SCIENCE (IAS 2021) HELD VIRTUALLY IN JULY 2021. TREAT ASIA DIRECTOR DR. ANNETTE SOHN MODERATED A SESSION THAT REVIEWED THE EVIDENCE BEHIND CURRENT TREATMENTS USED FOR COVID-19 AND ITS RELATED CONDITIONS, AND EXAMINED HOW THERAPEUTICS COULD BE RAPIDLY EVALUATED FOR COVID AND OTHER EMERGING INFECTIONS. DR. SOHN ALSO CO-CHAIRED A JOURNAL OF THE INTERNATIONAL AIDS SOCIETY SPECIAL SESSION ON THE CRITICAL ROLE OF IMPLEMENTATION SCIENCE IN THE HIV RESPONSE AND FOR GLOBAL GUIDELINES. NUMEROUS TREAT ASIA PARTNER INVESTIGATORS AND AFFILIATES ALSO GAVE POSTER PRESENTATIONS AT THE CONFERENCE.TREAT ASIA ALSO PARTICIPATED IN: THE 23RD BANGKOK INTERNATIONAL SYMPOSIUM ON HIV MEDICINE IN JANUARY 2021; THE INTERNATIONAL AIDS SOCIETY (IAS) COVID-19 CONFERENCE IN FEBRUARY; THE CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS (CROI) IN MARCH; AND THE SIXTH ASIA PACIFIC AIDS & CO-INFECTIONS CONFERENCE (APACC), HELD VIRTUALLY IN JUNE.	Desc

Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp

Field	Value	IRS element (for citing)
Expense	$3,085,757	ExpenseAmt
Grant	$0	GrantAmt
Revenue	$0	RevenueAmt
Desc	PUBLIC INFORMATION: AMFAR SEEKS TO TRANSLATE AND DISSEMINATE INFORMATION ON IMPORTANT HIV-RELATED RESEARCH, TREATMENT, PREVENTION, AND POLICY ISSUES FOR DIVERSE AUDIENCES AND TO INCREASE AWARENESS AND KNOWLEDGE OF THE PANDEMIC. AMFAR PUBLISHES A WIDE RANGE OF EDUCATIONAL MATERIALS, MAINTAINS AN INFORMATIVE WEBSITE, AND ENGAGES RESPECTED PUBLIC FIGURES, HIV/AIDS SCIENTISTS, AND POLICYMAKERS IN COMMUNICATING THE NEED FOR CONTINUED RESEARCH TO DEVELOP NEW METHODS OF PREVENTION, TREATMENT, AND, ULTIMATELY, A CURE FOR HIV. FOR FURTHER DETAILS, SEE SCHEDULE O. WHEN THE COVID-19 CRISIS EMERGED IN EARLY 2020, AMFAR DEDICATED A SECTION OF ITS WEBSITE TO INFORMATION ON THE CORONAVIRUS AND THE INTERSECTION OF HIV AND COVID-19 IN PARTICULAR. THE SECTION FEATURED RESOURCES FOR PEOPLE LIVING WITH HIV AND NEWS OF THE LATEST STUDIES AS MORE AND MORE DATA EMERGED. AUDIOVISUAL CONTENT INCLUDED A SERIES OF INTERVIEWSCONNECTIONS: COVID-19 AND HIVFEATURING INDIVIDUALS LIVING WITH HIV SHARING THEIR PERSONAL EXPERIENCES DURING THE COVID-19 PANDEMIC. THE INFORMATIVE SERIES GARNERED TENS OF THOUSANDS OF VIEWS. PUBLIC INFORMATION ALSO ASSISTED IN THE PRODUCTION OF INNOVATIVE VIRTUAL BENEFIT EVENTS INCLUDING A GALA FOR OUR TIME AND IT'S A SIN: A CONVERSATION IN MARCH 2021, AND FROM THE STUDIO PART II, AN ONLINE ART AUCTION IN PARTNERSHIP WITH CHRISTIE'S IN JULY 2021, AS WELL AS FUNDRAISING GALAS THAT WERE HELD IN PERSON IN CANNES, FRANCE, IN JULY 2021, AND VENICE, ITALY, IN SEPTEMBER. IN MAY 2021 AMFAR RECEIVED THE AWARD FOR OUTSTANDING DIGITAL THEATER, INDIVIDUAL PRODUCTION, AT THE 87TH DRAMA LEAGUE AWARDS FOR THE GREAT WORK BEGINS: SCENES FROM ANGELS IN AMERICA. AMFAR AND DIRECTOR ELLIE HEYMAN CAME TOGETHER IN 2020 TO PRODUCE THE VIRTUAL PERFORMANCE INSPIRED BY THE ICONIC TONY KUSHNER PLAY TO BENEFIT THE NEWLY FORMED AMFAR FUND TO FIGHT COVID-19. EDUCATIONAL MATERIALS AMFAR PRODUCES PERIODICALS IN BOTH PRINT AND ELECTRONIC FORMATS, INCLUDING ITS NEWSLETTER INNOVATIONS, PUBLISHED TWICE A YEAR AND DISTRIBUTED TO ABOUT 35,000 PEOPLE, AND A MONTHLY E-MAIL NEWSLETTER DISTRIBUTED TO APPROXIMATELY 16,000 PEOPLE. THE FOUNDATION'S WEBSITEWWW.AMFAR.ORGFEATURES NEWS, INTERVIEWS, AND ORIGINAL ARTICLES COVERING HIV RESEARCH, POLICY, THE GLOBAL EPIDEMIC, AND AMFAR PROGRAMS AND ACTIVITIES. THE WEBSITE ATTRACTS AN AVERAGE OF 25,000 VISITORS PER MONTH. AMFAR CREATES AND DISTRIBUTES REPORTS, PRESS RELEASES, AND UPDATES ON MAJOR HIV/AIDS ISSUES AND CONDUCTS PUBLIC SERVICE ADVERTISING CAMPAIGNS THAT HAVE BEEN INSTRUMENTAL IN EDUCATING POLICYMAKERS, HEALTHCARE PROFESSIONALS, PEOPLE LIVING WITH HIV/AIDS, AND THE PUBLIC. AMFAR'S PUBLIC INFORMATION TEAM ALSO WORKS CLOSELY WITH THE PUBLIC POLICY OFFICE (SEE ABOVE) TO PRODUCE A WIDE RANGE OF ISSUE BRIEFS, FACTS SHEETS, INFOGRAPHICS, AND REPORTS.EPIC VOICESAMFAR'S EPIC VOICES, AN ONLINE VIDEO SERIES THAT AIMS TO REENERGIZE THE RESPONSE TO HIV AMONG MILLENNIAL AND LGBTQ COMMUNITIES CONTINUED TO GENERATE SIGNIFICANT ENGAGEMENT THROUGHOUT THE YEAR. EPIC VOICES WON THE AWARD FOR VIDEO STORYTELLING IN THE 2021 PRNEWS CSR & NONPROFIT AWARDS. LAUNCHED IN 2017, THE GOALS OF THE CAMPAIGN ARE TO: RENEW AWARENESS OF THE PERSISTENT THREAT OF HIV, UNDERSCORE THE URGENT NEED TO SUPPORT HIV RESEARCH, AND SUPPORT AMFAR'S LEADERSHIP IN THE SEARCH FOR A CURE. AMFAR SPOKE TO HIV ACTIVISTS ACROSS THE COUNTRY AND ASKED THEM TO SHARE THEIR UNIQUE JOURNEYS, THEIR INSIGHTS ON LIVING WITH HIV, AND THE BOLD STEPS THEY HAVE TAKEN IN THE FIGHT AGAINST THE EPIDEMIC.SOCIAL MEDIAAMFAR HAS VIGOROUSLY EXPANDED ITS PRESENCE IN THE SOCIAL MEDIA ARENA, REACHING LARGE NUMBERS OF PEOPLE, INCLUDING A YOUNGER DEMOGRAPHIC THAT IS OFTEN LESS EDUCATED ABOUT HIV AND THE AIDS EPIDEMIC. THE FOUNDATION HAS EXPANDED ITS SOCIAL PLATFORMS TO INCLUDE TIKTOK, TARGETING THE NEW GENERATION OF ADVOCATES. AMFAR REGULARLY UPDATES ITS SOCIAL CHANNELS WITH THE LATEST RESEARCH BREAKTHROUGHS AND POLICY NEWS, AS WELL AS DETAILED COVERAGE FROM ITS WORLD-FAMOUS GALAS. AMFAR HAS OVER 78,000 LIKES ON FACEBOOK, MORE THAN 43,000 TWITTER FOLLOWERS, OVER 116,000 TIKTOK FOLLOWERS, AND 170,000 INSTAGRAM FOLLOWERS. MEDIA OUTREACHIN FY2021, AMFAR CONTINUED TO WORK CLOSELY WITH THE MEDIA TO RAISE THE PROFILE OF HIV/AIDS, BOTH DOMESTICALLY AND INTERNATIONALLY, AND TO HELP ENSURE THE ACCURACY OF HIV-RELATED PRESS COVERAGE. ARTICLES AND REPORTS INVOLVING AMFARMANY OF WHICH INCLUDED INTERVIEWS WITH STAFFWERE CARRIED IN NUMEROUS MEDIA OUTLETS, INCLUDING ABC NEWS, NBC NEWS, CNN, ASSOCIATED PRESS, REUTERS, THE NEW YORK TIMES, USA TODAY, U.S. NEWS & WORLD REPORT, VANITY FAIR, VOGUE, PEOPLE, VARIETY, CR FASHION BOOK, POZ MAGAZINE, WOMEN'S WEAR DAILY, US WEEKLY, THE HOLLYWOOD REPORTER, DEADLINE, YAHOO, PAGE SIX, DAILY MAIL, THE DAILY BEAST, AND THE HILL.CELEBRITY SUPPORT AMFAR'S PUBLIC AWARENESS EFFORTS ARE GREATLY ENHANCED BY THE COMMITTED SUPPORT OF PUBLIC FIGURES WHO LEND THEIR VOICES AND DONATE THEIR TIME, TALENTS, AND RESOURCES TO HELP SUSTAIN THE FOUNDATION'S MISSION. SUPPORT OF AMFAR BY PROMINENT PUBLIC FIGURES BEGAN WITH THE LATE DAME ELIZABETH TAYLOR, AMFAR'S FOUNDING INTERNATIONAL CHAIRMAN, AND OTHERS HAVE FOLLOWED IN HER FOOTSTEPS. AMFAR IS PROFOUNDLY GRATEFUL FOR THE CONTINUING SUPPORT OF CELEBRITIES FROM ALL OVER THE WORLD.CELEBRITY SUPPORTERS INCLUDED MARIA BAKALOVA, JORDAN BARRETT, SWIZZ BEATZ, DEREK BLASBERG, ORLANDO BLOOM, IAN BOHEN, NICHOLAS BRAUN, RACHEL BROSNAHAN, CINDY BRUNA, KELLY CLARKSON, GLENN CLOSE, DARREN CRISS, OLIVIA CULPO, LEE DANIELS, DIPLO, NINA DOBREV, JAY ELLIS, CYNTHIA ERIVO, MORGAN FREEMAN, EMILY HAMPSHIRE, JEREMY O. HARRIS, EMILE HIRSCH, TYLER HOECHLIN, JULIANNE HOUGH, MAGIC JOHNSON, ALICIA KEYS, REGINA KING, HEIDI KLUM, NATHAN LANE, SPIKE LEE, JULIAN LENNON, JULIANNA MARGULIES, AVA MAX, STELLA MAXWELL, BETTE MIDLER, CATHERINE O'HARA, RITA ORA, DYLAN PENN, JEREMY PIVEN, NATASHA POLY, BILLY PORTER, JULIA ROBERTS, MICHAELA JA RODRIGUEZ, CARINE ROITFELD, NICOLE SCHERZINGER, NINA SENICAR, SHARON STONE, BELLA THORNE, ELLEN VON UNWERTH, AND LYDIA WEST.	Desc

Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp

Field	Value	IRS element (for citing)
Expense	$1,722,628	ExpenseAmt
Grant	$190,233	GrantAmt
Revenue	$0	RevenueAmt

Field	Value	IRS element (for citing)
Total Other Prog Srvc Expense	$1,722,628	TotalOtherProgSrvcExpenseAmt
Total Other Prog Srvc Grant	$190,233	TotalOtherProgSrvcGrantAmt
Total Program Service Expenses	$20,160,685	TotalProgramServiceExpensesAmt
Described In Section501c3	Yes (1)	DescribedInSection501c3Ind
Schedule B Required	Yes (1)	ScheduleBRequiredInd
Political Campaign Acty	0	PoliticalCampaignActyInd
Lobbying Activities	Yes (1)	LobbyingActivitiesInd
Subject To Proxy Tax	0	SubjectToProxyTaxInd
Donor Advised Fund	0	DonorAdvisedFundInd
Conservation Easements	0	ConservationEasementsInd
Collections Of Art	Yes (1)	CollectionsOfArtInd
Credit Counseling	0	CreditCounselingInd
Donor Rstr Or Quasi Endowments	Yes (1)	DonorRstrOrQuasiEndowmentsInd
Report Land Building Equipment	Yes (1)	ReportLandBuildingEquipmentInd
Report Investments Other Sec	0	ReportInvestmentsOtherSecInd
Report Program Related Invst	0	ReportProgramRelatedInvstInd
Report Other Assets	0	ReportOtherAssetsInd
Report Other Liabilities	Yes (1)	ReportOtherLiabilitiesInd
Include FIN48 Footnote	Yes (1)	IncludeFIN48FootnoteInd
Independent Audit Fincl Stmt	Yes (1)	IndependentAuditFinclStmtInd
Consolidated Audit Fincl Stmt	0	ConsolidatedAuditFinclStmtInd
School Operating	0	SchoolOperatingInd
Foreign Office	Yes (1)	ForeignOfficeInd
Foreign Activities	Yes (1)	ForeignActivitiesInd
More Than5000 K To Org	Yes (1)	MoreThan5000KToOrgInd
More Than5000 K To Individuals	0	MoreThan5000KToIndividualsInd
Professional Fundraising	Yes (1)	ProfessionalFundraisingInd
Fundraising Activities	Yes (1)	FundraisingActivitiesInd
Gaming Activities	0	GamingActivitiesInd
Operate Hospital	0	OperateHospitalInd
Grants To Organizations	Yes (1)	GrantsToOrganizationsInd
Grants To Individuals	0	GrantsToIndividualsInd
Schedule J Required	Yes (1)	ScheduleJRequiredInd
Tax Exempt Bonds	0	TaxExemptBondsInd
Engaged In Excess Benefit Trans	0	EngagedInExcessBenefitTransInd
PY Excess Benefit Trans	0	PYExcessBenefitTransInd
Loan Outstanding	0	LoanOutstandingInd
Grant To Related Person	0	GrantToRelatedPersonInd
Business Rln With Org Mem	0	BusinessRlnWithOrgMemInd
Business Rln With Fam Mem	0	BusinessRlnWithFamMemInd
Business Rln With35 Ctrl Ent	0	BusinessRlnWith35CtrlEntInd
Deductible Non Cash Contri	Yes (1)	DeductibleNonCashContriInd
Deductible Art Contribution	0	DeductibleArtContributionInd
Terminate Operations	0	TerminateOperationsInd
Partial Liquidation	0	PartialLiquidationInd
Disregarded Entity	0	DisregardedEntityInd
Related Entity	0	RelatedEntityInd
Related Organization Ctrl Ent	0	RelatedOrganizationCtrlEntInd
Trnsfr Exmpt Non Chrtbl Rltd Org	0	TrnsfrExmptNonChrtblRltdOrgInd
Activities Conducted Prtshp	0	ActivitiesConductedPrtshpInd
Schedule O Required	Yes (1)	ScheduleORequiredInd
IRP Document	85	IRPDocumentCnt
IRP Document W2 G	0	IRPDocumentW2GCnt
Backup Wthld Compliance	Yes (1)	BackupWthldComplianceInd
Employee	79	EmployeeCnt
Employment Tax Returns Filed	Yes (1)	EmploymentTaxReturnsFiledInd
Unrelated Bus Incm Over Limit	0	UnrelatedBusIncmOverLimitInd
Foreign Financial Account	Yes (1)	ForeignFinancialAccountInd
Foreign Country	TH	ForeignCountryCd
Prohibited Tax Shelter Trans	0	ProhibitedTaxShelterTransInd
Taxable Party Notification	0	TaxablePartyNotificationInd
Nondeductible Contributions	0	NondeductibleContributionsInd
Quid Pro Quo Contributions	Yes (1)	QuidProQuoContributionsInd
Quid Pro Quo Contri Discl	Yes (1)	QuidProQuoContriDisclInd
Form8282 Property Disposed Of	0	Form8282PropertyDisposedOfInd
Rcv Fnds To Pay Prsnl Bnft Cntrct	0	RcvFndsToPayPrsnlBnftCntrctInd
Pay Premiums Prsnl Bnft Cntrct	0	PayPremiumsPrsnlBnftCntrctInd
Indoor Tanning Services	0	IndoorTanningServicesInd
Subj To Tax Rmnrtn Ex Prcht Pymt	0	SubjToTaxRmnrtnExPrchtPymtInd
Subject To Excs Tax Net Invst Inc	0	SubjectToExcsTaxNetInvstIncInd
Info In Schedule O Part VI	Yes (X)	InfoInScheduleOPartVIInd
Governing Body Voting Members	17	GoverningBodyVotingMembersCnt
Independent Voting Member	17	IndependentVotingMemberCnt
Family Or Business Rln	0	FamilyOrBusinessRlnInd
Delegation Of Mgmt Duties	0	DelegationOfMgmtDutiesInd
Change To Org Documents	0	ChangeToOrgDocumentsInd
Material Diversion Or Misuse	0	MaterialDiversionOrMisuseInd
Members Or Stockholders	0	MembersOrStockholdersInd
Election Of Board Members	0	ElectionOfBoardMembersInd
Decisions Subject To Approva	0	DecisionsSubjectToApprovaInd
Minutes Of Governing Body	Yes (1)	MinutesOfGoverningBodyInd
Minutes Of Committees	Yes (1)	MinutesOfCommitteesInd
Officer Mailing Address	0	OfficerMailingAddressInd
Local Chapters	0	LocalChaptersInd
Form990 Provided To Gvrn Body	Yes (1)	Form990ProvidedToGvrnBodyInd
Conflict Of Interest Policy	Yes (1)	ConflictOfInterestPolicyInd
Annual Disclosure Covered Prsn	Yes (1)	AnnualDisclosureCoveredPrsnInd
Regular Monitoring Enfrc	Yes (1)	RegularMonitoringEnfrcInd
Whistleblower Policy	Yes (1)	WhistleblowerPolicyInd
Document Retention Policy	Yes (1)	DocumentRetentionPolicyInd
Compensation Process CEO	Yes (1)	CompensationProcessCEOInd
Compensation Process Other	Yes (1)	CompensationProcessOtherInd
Investment In Joint Venture	0	InvestmentInJointVentureInd
States Where Copy Of Return Is Fld	AL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	AR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	CA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	DC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	FL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	GA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	HI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	IL	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	KY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MD	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	MS	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NH	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NJ	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NM	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	NY	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OK	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	OR	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	PA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	RI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	SC	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TN	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	TX	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	UT	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	VA	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WI	StatesWhereCopyOfReturnIsFldCd
States Where Copy Of Return Is Fld	WV	StatesWhereCopyOfReturnIsFldCd
Own Website	Yes (X)	OwnWebsiteInd
Upon Request	Yes (X)	UponRequestInd

Books In Care Of Detail BooksInCareOfDetail

Business Name BusinessName

Field	Value	IRS element (for citing)
Business Name Line1	BRADLEY JENSEN	BusinessNameLine1Txt

Field	Value	IRS element (for citing)
Phone	2128061703	PhoneNum

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	120 WALL STREET 13TH FLOOR	AddressLine1Txt
City	NEW YORK	CityNm
State Abbreviation	NY	StateAbbreviationCd
ZIP	100053908	ZIPCd

Form990 Part VII Section A Form990PartVIISectionAGrp (32 entries)

TitleTitleTxt	Average Hours Per WeekAverageHoursPerWeekRt	Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt	Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd	OfficerOfficerInd	Reportable Comp From OrgReportableCompFromOrgAmt	Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt	Other CompensationOtherCompensationAmt	Key EmployeeKeyEmployeeInd	Highest Compensated EmployeeHighestCompensatedEmployeeInd
T RYAN GREENWALT
CO-CHAIR	1.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
KEVIN MCCLATCHY
CO-CHAIR	1.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
RAYMOND F SCHINAZI PHD
TREASURER (THRU 02/21)	1.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
JAY ELLIS
SECRETARY	1.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
DANIELLE ALEXANDRA
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
AMY ANDELSON
TRUSTEE (AS OF 02/2021)	1.00	0.00	Yes (X)		$0	$0	$0
DAVID BOHNETT
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
DONALD DYE
TREASURER	1.00	0.00	Yes (X)	Yes (X)	$0	$0	$0
GLENN ISAACSON
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
MICHAEL LORBER
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
LARRY MILSTEIN
TRUSTEE (AS OF 02/2021)	1.00	0.00	Yes (X)		$0	$0	$0
BILLY PORTER
TRUSTEE (AS OF 02/2021)	1.00	0.00	Yes (X)		$0	$0	$0
VINCENT A ROBERTI
TRUSTEE (AS OF 06/2021)	1.00	0.00	Yes (X)		$0	$0	$0
JEFFREY SCHOENFELD
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
MARIO STEVENSON
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
ROBERT L TRAYNHAM II
TRUSTEE (AS OF 02/2021)	1.00	0.00	Yes (X)		$0	$0	$0
PHILL WILSON
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
MERV SILVERMAN
TRUSTEE	1.00	0.00	Yes (X)		$0	$0	$0
KEVIN FROST
CHIEF EXECUTIVE OFFICER	40.00	0.00		Yes (X)	$487,643	$0	$101,537
BRADLEY JENSEN
ASSISTANT TREASURER/CFO	40.00	0.00		Yes (X)	$267,465	$0	$67,809
ROWENA JOHNSTON
ASST SEC, VP, RESEARCH	40.00	0.00		Yes (X)	$211,292	$0	$35,230
SEBASTIAN GHEITH
ASSOCIATE COUNSEL, ASST SECRETARY	40.00	0.00		Yes (X)	$172,886	$0	$74,770
EDWARD DONNELLY
ASST TREASURER, CONTROLLER	40.00	0.00		Yes (X)	$170,841	$0	$30,937
ANNETTE SOHN
VICE PRESIDENT, TREAT ASIA	40.00	0.00			$254,537	$0	$26,432	Yes (X)
ANNMARIE SHANNAHAN
VICE PRESIDENT, PUBLIC INFO	40.00	0.00			$241,584	$0	$65,330	Yes (X)
ERIC MUSCATELL THRU 073120
VICE PRESIDENT OF DEVELOPMENT	40.00	0.00			$155,651	$0	$35,651	Yes (X)
GREGORIO MILLET
VICE PRESIDENT, PUBLIC POLICY	40.00	0.00			$186,031	$0	$62,613	Yes (X)
JONATHAN KEY THRU 101320
DIRECTOR, PHILANTHROPY	40.00	0.00			$225,212	$0	$23,284		Yes (X)
ANDREW MCINNESS
DIRECTOR, PUBLICATIONS	40.00	0.00			$173,945	$0	$74,776		Yes (X)
ANTHONY ANCONA
VICE PRESIDENT, HR	40.00	0.00			$194,456	$0	$61,984		Yes (X)
BENNAH SERFATY
SENIOR DIRECTOR OF COMMUNICATIONS	40.00	0.00			$136,970	$0	$72,173		Yes (X)
SUE DOSTER
CHIEF TECHNOLOGY OFFICER	40.00	0.00			$157,903	$0	$31,619		Yes (X)

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	$3,036,416	TotalReportableCompFromOrgAmt
Tot Reportable Comp Rltd Org	$0	TotReportableCompRltdOrgAmt
Total Other Compensation	$764,145	TotalOtherCompensationAmt
Indiv Rcvd Greater Than100 K	28	IndivRcvdGreaterThan100KCnt
Former Ofcr Employees Listed	0	FormerOfcrEmployeesListedInd
Total Comp Greater Than150 K	Yes (1)	TotalCompGreaterThan150KInd
Compensation From Other Srcs	0	CompensationFromOtherSrcsInd

Contractor Compensation ContractorCompensationGrp (4 entries)

Address Line1ContractorAddress/USAddress/AddressLine1Txt	CityContractorAddress/USAddress/CityNm	State AbbreviationContractorAddress/USAddress/StateAbbreviationCd	ZIPContractorAddress/USAddress/ZIPCd	ServicesServicesDesc	CompensationCompensationAmt
SANKY COMMUNICATIONS INC
599 11TH AVENUE 6TH FLOOR	NEW YORK	NY	10036	DIRECT MAIL/RESPONSE CONSULTANTS	$326,775
AAB PRODUCTION INC
64 ALLEN ROAD 5TH FLOOR	NEW YORK	NY	10002	EVENTS PRODUCTION	$148,243
GRANT THORNTON LLP
33570 TREASURY CENTER	CHICAGO	IL	606943500	ACCOUNTING AND AUDIT	$134,037
MICHAEL NEVIN
115 NORTH 7TH STREET 2	BROOKYLN	NY	11249	ART CURATION	$120,000

Field	Value	IRS element (for citing)
Cntrct Rcvd Greater Than100 K	4	CntrctRcvdGreaterThan100KCnt
Federated Campaigns	$113,225	FederatedCampaignsAmt
Fundraising	$9,885,493	FundraisingAmt
Government Grants	$11,131,282	GovernmentGrantsAmt
All Other Contributions	$7,066,461	AllOtherContributionsAmt
Noncash Contributions	$217,327	NoncashContributionsAmt
Total Contributions	$28,196,461	TotalContributionsAmt

Investment Income InvestmentIncomeGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$988,795	TotalRevenueColumnAmt
Exclusion	$988,795	ExclusionAmt

Royalties Revenue RoyaltiesRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$36,205	TotalRevenueColumnAmt
Exclusion	$36,205	ExclusionAmt

Gross Amount Sales Assets GrossAmountSalesAssetsGrp

Field	Value	IRS element (for citing)
Securities	$14,542,828	SecuritiesAmt

Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp

Field	Value	IRS element (for citing)
Securities	$12,868,645	SecuritiesAmt

Gain Or Loss GainOrLossGrp

Field	Value	IRS element (for citing)
Securities	$1,674,183	SecuritiesAmt

Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$1,674,183	TotalRevenueColumnAmt
Exclusion	$1,674,183	ExclusionAmt

Field	Value	IRS element (for citing)
Fundraising Gross Income	$318,000	FundraisingGrossIncomeAmt
Contri Rpt Fundraising Event	$9,885,493	ContriRptFundraisingEventAmt
Fundraising Direct Expenses	$7,711,074	FundraisingDirectExpensesAmt

Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp

Field	Value	IRS element (for citing)
Total Revenue Column	-$7,393,074	TotalRevenueColumnAmt
Exclusion	-$7,393,074	ExclusionAmt

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	$28,456	GrossSalesOfInventoryAmt
Cost Of Goods Sold	$7,425	CostOfGoodsSoldAmt

Net Income Or Loss NetIncomeOrLossGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$21,031	TotalRevenueColumnAmt
Exclusion	$21,031	ExclusionAmt

Other Revenue Misc OtherRevenueMiscGrp

Field	Value	IRS element (for citing)
Desc	STORE SALES	Desc
Business	900099	BusinessCd
Total Revenue Column	$1,303	TotalRevenueColumnAmt
Exclusion	$1,303	ExclusionAmt

Miscellaneous Revenue MiscellaneousRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$6,555	TotalRevenueColumnAmt
Exclusion	$6,555	ExclusionAmt

Field	Value	IRS element (for citing)
Other Revenue Total	$7,858	OtherRevenueTotalAmt

Total Revenue TotalRevenueGrp

Field	Value	IRS element (for citing)
Total Revenue Column	$23,531,459	TotalRevenueColumnAmt
Related Or Exempt Func Income	$0	RelatedOrExemptFuncIncomeAmt
Unrelated Business Revenue	$0	UnrelatedBusinessRevenueAmt
Exclusion	-$4,665,002	ExclusionAmt

Field	Value	IRS element (for citing)
Info In Schedule O Part IX	Yes (X)	InfoInScheduleOPartIXInd

Grants To Domestic Orgs GrantsToDomesticOrgsGrp

Field	Value	IRS element (for citing)
Total	$3,959,742	TotalAmt
Program Services	$3,959,742	ProgramServicesAmt

Foreign Grants ForeignGrantsGrp

Field	Value	IRS element (for citing)
Total	$2,355,109	TotalAmt
Program Services	$2,355,109	ProgramServicesAmt

Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp

Field	Value	IRS element (for citing)
Total	$2,892,890	TotalAmt
Program Services	$2,096,810	ProgramServicesAmt
Management And General	$360,143	ManagementAndGeneralAmt
Fundraising	$435,937	FundraisingAmt

Other Salaries And Wages OtherSalariesAndWagesGrp

Field	Value	IRS element (for citing)
Total	$5,672,306	TotalAmt
Program Services	$3,623,510	ProgramServicesAmt
Management And General	$666,970	ManagementAndGeneralAmt
Fundraising	$1,381,826	FundraisingAmt

Pension Plan Contributions PensionPlanContributionsGrp

Field	Value	IRS element (for citing)
Total	$367,459	TotalAmt
Program Services	$247,056	ProgramServicesAmt
Management And General	$46,742	ManagementAndGeneralAmt
Fundraising	$73,661	FundraisingAmt

Other Employee Benefits OtherEmployeeBenefitsGrp

Field	Value	IRS element (for citing)
Total	$1,835,965	TotalAmt
Program Services	$1,207,277	ProgramServicesAmt
Management And General	$273,116	ManagementAndGeneralAmt
Fundraising	$355,572	FundraisingAmt

Payroll Taxes PayrollTaxesGrp

Field	Value	IRS element (for citing)
Total	$530,028	TotalAmt
Program Services	$331,873	ProgramServicesAmt
Management And General	$69,050	ManagementAndGeneralAmt
Fundraising	$129,105	FundraisingAmt

Fees For Services Legal FeesForServicesLegalGrp

Field	Value	IRS element (for citing)
Total	$81,778	TotalAmt
Program Services	$74,097	ProgramServicesAmt
Management And General	$7,645	ManagementAndGeneralAmt
Fundraising	$36	FundraisingAmt

Fees For Services Accounting FeesForServicesAccountingGrp

Field	Value	IRS element (for citing)
Total	$188,522	TotalAmt
Management And General	$188,522	ManagementAndGeneralAmt

Fees For Services Lobbying FeesForServicesLobbyingGrp

Field	Value	IRS element (for citing)
Total	$8,015	TotalAmt
Program Services	$8,015	ProgramServicesAmt

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	$428,334	TotalAmt
Fundraising	$428,334	FundraisingAmt

Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp

Field	Value	IRS element (for citing)
Total	$239,987	TotalAmt
Management And General	$239,987	ManagementAndGeneralAmt

Fees For Services Other FeesForServicesOtherGrp

Field	Value	IRS element (for citing)
Total	$724,599	TotalAmt
Program Services	$238,730	ProgramServicesAmt
Management And General	$22,196	ManagementAndGeneralAmt
Fundraising	$463,673	FundraisingAmt

Advertising AdvertisingGrp

Field	Value	IRS element (for citing)
Total	$181,188	TotalAmt
Program Services	$121,980	ProgramServicesAmt
Management And General	$415	ManagementAndGeneralAmt
Fundraising	$58,793	FundraisingAmt

Office Expenses OfficeExpensesGrp

Field	Value	IRS element (for citing)
Total	$9,771	TotalAmt
Program Services	$5,330	ProgramServicesAmt
Management And General	$896	ManagementAndGeneralAmt
Fundraising	$3,545	FundraisingAmt

Information Technology InformationTechnologyGrp

Field	Value	IRS element (for citing)
Total	$537,117	TotalAmt
Program Services	$268,609	ProgramServicesAmt
Management And General	$50,794	ManagementAndGeneralAmt
Fundraising	$217,714	FundraisingAmt

Occupancy OccupancyGrp

Field	Value	IRS element (for citing)
Total	$1,630,298	TotalAmt
Program Services	$1,096,072	ProgramServicesAmt
Management And General	$208,313	ManagementAndGeneralAmt
Fundraising	$325,913	FundraisingAmt

Travel TravelGrp

Field	Value	IRS element (for citing)
Total	$455,146	TotalAmt
Program Services	$116,013	ProgramServicesAmt
Management And General	$196	ManagementAndGeneralAmt
Fundraising	$338,937	FundraisingAmt

Conferences Meetings ConferencesMeetingsGrp

Field	Value	IRS element (for citing)
Total	$92,899	TotalAmt
Program Services	$64,299	ProgramServicesAmt
Management And General	$184	ManagementAndGeneralAmt
Fundraising	$28,416	FundraisingAmt

Interest InterestGrp

Field	Value	IRS element (for citing)
Total	$10,258	TotalAmt
Program Services	$7,192	ProgramServicesAmt
Management And General	$1,368	ManagementAndGeneralAmt
Fundraising	$1,698	FundraisingAmt

Depreciation Depletion DepreciationDepletionGrp

Field	Value	IRS element (for citing)
Total	$417,260	TotalAmt
Program Services	$292,526	ProgramServicesAmt
Management And General	$55,645	ManagementAndGeneralAmt
Fundraising	$69,089	FundraisingAmt

Insurance InsuranceGrp

Field	Value	IRS element (for citing)
Total	$264,223	TotalAmt
Program Services	$185,237	ProgramServicesAmt
Management And General	$35,237	ManagementAndGeneralAmt
Fundraising	$43,749	FundraisingAmt

Other Expenses OtherExpensesGrp (3 entries)

DescDesc	TotalTotalAmt	Program ServicesProgramServicesAmt	Management And GeneralManagementAndGeneralAmt	FundraisingFundraisingAmt
PROGRAM MATERIALS	$2,439,915	$2,439,915
PROG. TECHNICAL SUPPORT	$652,581	$652,581
POSTAGE & SHIPPING	$399,832	$214,415	$2,881	$182,536

All Other Expenses AllOtherExpensesGrp

Field	Value	IRS element (for citing)
Total	$1,296,728	TotalAmt
Program Services	$554,297	ProgramServicesAmt
Management And General	$327,191	ManagementAndGeneralAmt
Fundraising	$415,240	FundraisingAmt

Total Functional Expenses TotalFunctionalExpensesGrp

Field	Value	IRS element (for citing)
Total	$27,671,950	TotalAmt
Program Services	$20,160,685	ProgramServicesAmt
Management And General	$2,557,491	ManagementAndGeneralAmt
Fundraising	$4,953,774	FundraisingAmt

Field	Value	IRS element (for citing)
Joint Costs	Yes (X)	JointCostsInd

Cash Non Interest Bearing CashNonInterestBearingGrp

Field	Value	IRS element (for citing)
BOY	$3,725,042	BOYAmt
EOY	$2,387,272	EOYAmt

Savings And Temp Cash Invst SavingsAndTempCashInvstGrp

Field	Value	IRS element (for citing)
BOY	$1,607,204	BOYAmt
EOY	$1,250,013	EOYAmt

Pledges And Grants Receivable PledgesAndGrantsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$639,936	BOYAmt
EOY	$558,346	EOYAmt

Accounts Receivable AccountsReceivableGrp

Field	Value	IRS element (for citing)
BOY	$3,839,668	BOYAmt
EOY	$5,657,274	EOYAmt

Inventories For Sale Or Use InventoriesForSaleOrUseGrp

Field	Value	IRS element (for citing)
BOY	$493,291	BOYAmt
EOY	$560,116	EOYAmt

Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp

Field	Value	IRS element (for citing)
BOY	$1,159,569	BOYAmt
EOY	$2,392,167	EOYAmt

Field	Value	IRS element (for citing)
Land Bldg Equip Cost Or Other Bss	$7,760,218	LandBldgEquipCostOrOtherBssAmt
Land Bldg Equip Accum Deprec	$5,268,592	LandBldgEquipAccumDeprecAmt

Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp

Field	Value	IRS element (for citing)
BOY	$2,925,831	BOYAmt
EOY	$2,491,626	EOYAmt

Investments Pub Traded Sec InvestmentsPubTradedSecGrp

Field	Value	IRS element (for citing)
BOY	$39,141,898	BOYAmt
EOY	$40,066,573	EOYAmt

Other Assets Total OtherAssetsTotalGrp

Field	Value	IRS element (for citing)
BOY	$1,207,079	BOYAmt
EOY	$480,208	EOYAmt

Total Assets TotalAssetsGrp

Field	Value	IRS element (for citing)
BOY	$54,739,518	BOYAmt
EOY	$55,843,595	EOYAmt

Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp

Field	Value	IRS element (for citing)
BOY	$2,489,524	BOYAmt
EOY	$2,834,273	EOYAmt

Grants Payable GrantsPayableGrp

Field	Value	IRS element (for citing)
BOY	$1,052,816	BOYAmt
EOY	$1,246,435	EOYAmt

Deferred Revenue DeferredRevenueGrp

Field	Value	IRS element (for citing)
BOY	$6,138,184	BOYAmt
EOY	$7,916,273	EOYAmt

Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp

Field	Value	IRS element (for citing)
EOY	$3,509,082	EOYAmt

Other Liabilities OtherLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$3,413,100	BOYAmt
EOY	$1,717,253	EOYAmt

Total Liabilities TotalLiabilitiesGrp

Field	Value	IRS element (for citing)
BOY	$13,093,624	BOYAmt
EOY	$17,223,316	EOYAmt

Field	Value	IRS element (for citing)
Organization Follows FASB117	Yes (X)	OrganizationFollowsFASB117Ind

No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$37,674,119	BOYAmt
EOY	$35,366,530	EOYAmt

Donor Restriction Net Assets DonorRestrictionNetAssetsGrp

Field	Value	IRS element (for citing)
BOY	$3,971,775	BOYAmt
EOY	$3,253,749	EOYAmt

Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$41,645,894	BOYAmt
EOY	$38,620,279	EOYAmt

Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp

Field	Value	IRS element (for citing)
BOY	$54,739,518	BOYAmt
EOY	$55,843,595	EOYAmt

Field	Value	IRS element (for citing)
Reconcilation Revenue Expnss	-$4,140,491	ReconcilationRevenueExpnssAmt
Net Unrlzd Gains Losses Invst	$1,114,876	NetUnrlzdGainsLossesInvstAmt
Other Changes In Net Assets	$0	OtherChangesInNetAssetsAmt
Method Of Accounting Accrual	Yes (X)	MethodOfAccountingAccrualInd
Accountant Compile Or Review	0	AccountantCompileOrReviewInd
FS Audited	Yes (1)	FSAuditedInd

FS Audited Basis FSAuditedBasisGrp

Field	Value	IRS element (for citing)
Separate Basis Fincl Stmt	Yes (X)	SeparateBasisFinclStmtInd

Field	Value	IRS element (for citing)
Audit Committee	Yes (1)	AuditCommitteeInd
Federal Grant Audit Required	Yes (1)	FederalGrantAuditRequiredInd
Federal Grant Audit Performed	Yes (1)	FederalGrantAuditPerformedInd

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Public Organization170	Yes (X)	PublicOrganization170Ind

Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$50,842,378	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$42,784,390	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$40,275,703	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$21,630,486	CurrentTaxYearMinus1YearAmt
Current Tax Year	$28,196,461	CurrentTaxYearAmt
Total	$183,729,418	TotalAmt

Total Calendar Year170 TotalCalendarYear170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$50,842,378	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$42,784,390	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$40,275,703	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$21,630,486	CurrentTaxYearMinus1YearAmt
Current Tax Year	$28,196,461	CurrentTaxYearAmt
Total	$183,729,418	TotalAmt

Field	Value	IRS element (for citing)
Public Support Total170	$183,729,418	PublicSupportTotal170Amt

Gross Investment Income170 GrossInvestmentIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$1,354,513	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$1,590,672	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$1,538,331	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$1,252,653	CurrentTaxYearMinus1YearAmt
Current Tax Year	$1,025,000	CurrentTaxYearAmt
Total	$6,761,169	TotalAmt

Other Income170 OtherIncome170Grp

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	$1,819,001	CurrentTaxYearMinus4YearsAmt
Current Tax Year Minus3 Years	$2,097,498	CurrentTaxYearMinus3YearsAmt
Current Tax Year Minus2 Years	$1,822,760	CurrentTaxYearMinus2YearsAmt
Current Tax Year Minus1 Year	$858,301	CurrentTaxYearMinus1YearAmt
Current Tax Year	$354,316	CurrentTaxYearAmt
Total	$6,951,876	TotalAmt

Field	Value	IRS element (for citing)
Total Support	$197,442,463	TotalSupportAmt
Gross Receipts Rltd Activities	$197,337,817	GrossReceiptsRltdActivitiesAmt
Public Support CY170	0.93050	PublicSupportCY170Pct
Public Support PY170	0.93100	PublicSupportPY170Pct
Thirty Thr Pct Suprt Tests CY170	Yes (X)	ThirtyThrPctSuprtTestsCY170Ind

Form990 Schedule A Part VI Form990ScheduleAPartVIGrp

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME:	FormAndLineReferenceDesc
Explanation	MISCELLANEOUS - 2016 AMOUNT: $ 3,788. 2017 AMOUNT: $ 396. 2018 AMOUNT: $ 1,267. 2019 AMOUNT: $ 165. 2020 AMOUNT: $ 6,557. LIST RENTALS - 2016 AMOUNT: $ 3,691. 2017 AMOUNT: $ 2,793. 2018 AMOUNT: $ 170. 2019 AMOUNT: $ 2,201. 2020 AMOUNT: $ 0. INVENTORY - 2016 AMOUNT: $ 13,222. 2017 AMOUNT: $ 48,094. 2018 AMOUNT: $ 25,294. 2019 AMOUNT: $ 18,379. 2020 AMOUNT: $ 28,456. SPECIAL EVENTS - 2016 AMOUNT: $ 1,797,050. 2017 AMOUNT: $ 2,043,540. 2018 AMOUNT: $ 1,794,170. 2019 AMOUNT: $ 836,855. 2020 AMOUNT: $ 318,000. STORE SALES - 2016 AMOUNT: $ 1,250. 2017 AMOUNT: $ 2,675. 2018 AMOUNT: $ 1,859. 2019 AMOUNT: $ 701. 2020 AMOUNT: $ 1,303.	ExplanationTxt

Schedule B IRS990ScheduleB

Contributor Information ContributorInformationGrp

Field	Value	IRS element (for citing)
Contributor	RESTRICTED	ContributorNum

Contributor Business Name ContributorBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor US Address ContributorUSAddress

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Total Contributions	RESTRICTED	TotalContributionsAmt

Schedule C IRS990ScheduleC

Field	Value	IRS element (for citing)
Volunteers	0	VolunteersInd
Paid Staff Or Management	Yes (1)	PaidStaffOrManagementInd
Media Advertisements	0	MediaAdvertisementsInd
Mailings Members	0	MailingsMembersInd
Publications Or Broadcast	0	PublicationsOrBroadcastInd
Grants Other Organizations	0	GrantsOtherOrganizationsInd
Direct Contact Legislators	0	DirectContactLegislatorsInd
Rallies Demonstrations	0	RalliesDemonstrationsInd
Other Activities	Yes (1)	OtherActivitiesInd
Other Activities	$190,738	OtherActivitiesAmt
Total Lobbying Expenditures	$190,738	TotalLobbyingExpendituresAmt
Not Described Section501c3	0	NotDescribedSection501c3Ind

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART II-B, LINE 1:	FormAndLineReferenceDesc
Explanation	THE FOUNDATION FOR AIDS RESEARCH DEVELOPED AN ACTION AGENDA TO END AIDS THAT IDENTIFIED CRITICAL DECISIONS THAT NEED TO BE MADE TO ADVANCE EVIDENCE BASED AIDS POLICIES. WE CREATED A VARIETY OF ISSUE BRIEFS ON TOPICS SUCH AS THE POTENTIAL IMPACT OF VARIOUS BUDGET SCENARIOS ON GLOBAL HEALTH SERVICES, AND POLICY PRIORITIES TO ADDRESS THE HIV EPIDEMIC AMONG GAY MEN IN THE US. THESE ISSUE BRIEFS WERE SHARED WITH CAPITOL HILL STAFF AND MEMBERS OF THE ADMINISTRATION. AMFAR MET REGULARLY WITH STAFF TO MEMBERS OF CONGRESS AND WITH ADMINISTRATION STAFF, AND WE PROVIDED INPUT TO THE ADMINISTRATION ON DEVELOPMENT OF THE PEPFAR BLUEPRINT FOR AN AIDS FREE GENERATION. AMFAR SPONSORED SEVERAL BRIEFINGS ON CAPITOL HILL ON AIDS POLICY AND RESEARCH ISSUES. AMFAR USES THESE BRIEFINGS AS AN EDUCATIONAL TOOL. THE FOUNDATION ENGAGED AN INDEPENDENT CONSULTANT TO ENGAGE IN LOBBYING ACTIVITIES ON ITS BEHALF. FEES PAID TO THIS CONSULTANT TOTALED $8,015 IN THE FISCAL YEAR ENDING SEPTEMBER 30, 2021.	ExplanationTxt

Schedule D IRS990ScheduleD

Art Public Exhibition Amounts ArtPublicExhibitionAmountsGrp

Field	Value	IRS element (for citing)
Assets Included	$622,351	AssetsIncludedAmt

Collection Used Other Purposes CollectionUsedOtherPurposesGrp

Field	Value	IRS element (for citing)
Collection Used Other Purposes	Yes (X)	CollectionUsedOtherPurposesInd
Other Purposes	DONATED ITEMS, INVENTORY ETC.	OtherPurposesDesc

Field	Value	IRS element (for citing)
Solicited Assets Sale	Yes (1)	SolicitedAssetsSaleInd

CY Endwmt Fund CYEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$731,736	BeginningYearBalanceAmt
Contributions	$5,380	ContributionsAmt
Investment Earnings Or Losses	$48,499	InvestmentEarningsOrLossesAmt
End Year Balance	$785,615	EndYearBalanceAmt

CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$701,368	BeginningYearBalanceAmt
Contributions	$7,933	ContributionsAmt
Investment Earnings Or Losses	$22,435	InvestmentEarningsOrLossesAmt
End Year Balance	$731,736	EndYearBalanceAmt

CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$684,111	BeginningYearBalanceAmt
Contributions	$6,750	ContributionsAmt
Investment Earnings Or Losses	$10,507	InvestmentEarningsOrLossesAmt
End Year Balance	$701,368	EndYearBalanceAmt

CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$593,133	BeginningYearBalanceAmt
Contributions	$4,100	ContributionsAmt
Investment Earnings Or Losses	$86,877	InvestmentEarningsOrLossesAmt
End Year Balance	$684,110	EndYearBalanceAmt

CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp

Field	Value	IRS element (for citing)
Beginning Year Balance	$541,231	BeginningYearBalanceAmt
Contributions	$5,950	ContributionsAmt
Investment Earnings Or Losses	$45,952	InvestmentEarningsOrLossesAmt
End Year Balance	$593,133	EndYearBalanceAmt

Field	Value	IRS element (for citing)
Board Designated Balance EOY	0.00000	BoardDesignatedBalanceEOYPct
Prmnnt Endowment Balance EOY	0.49980	PrmnntEndowmentBalanceEOYPct
Term Endowment Balance EOY	0.50020	TermEndowmentBalanceEOYPct
Endowments Held Unrelated Org	0	EndowmentsHeldUnrelatedOrgInd
Endowments Held Related Org	0	EndowmentsHeldRelatedOrgInd

Leasehold Improvements LeaseholdImprovementsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$2,542,490	OtherCostOrOtherBasisAmt
Depreciation	$1,735,397	DepreciationAmt
Book Value	$807,093	BookValueAmt

Equipment EquipmentGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$307,521	OtherCostOrOtherBasisAmt
Depreciation	$305,823	DepreciationAmt
Book Value	$1,698	BookValueAmt

Other Land Buildings OtherLandBuildingsGrp

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	$4,910,207	OtherCostOrOtherBasisAmt
Depreciation	$3,227,372	DepreciationAmt
Book Value	$1,682,835	BookValueAmt

Field	Value	IRS element (for citing)
Total Book Value Land Buildings	$2,491,626	TotalBookValueLandBuildingsAmt

Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)

DescDesc	AmtAmt
LONG TERM LEASE LIABILITY	$1,316,127
SEC. 457 RETIREMENT LIABILITY	$401,126

Field	Value	IRS element (for citing)
Total Liability	$1,717,253	TotalLiabilityAmt
Footnote Text	Yes (X)	FootnoteTextInd
Total Rev Etc Audited Fincl Stmt	$24,441,148	TotalRevEtcAuditedFinclStmtAmt
Net Unrealized Gains Invst	$1,114,876	NetUnrealizedGainsInvstAmt
Donated Services And Use Fclts	$34,800	DonatedServicesAndUseFcltsAmt
Revenue Not Reported	$1,149,676	RevenueNotReportedAmt
Revenue Subtotal	$23,291,472	RevenueSubtotalAmt
Investment Expenses Not Incld	$239,987	InvestmentExpensesNotIncldAmt
Revenue Not Reported Fincl Stmt	$239,987	RevenueNotReportedFinclStmtAmt
Total Revenue Per Form990	$23,531,459	TotalRevenuePerForm990Amt
Tot Expns Etc Audited Fincl Stmt	$27,466,763	TotExpnsEtcAuditedFinclStmtAmt
Donated Services Use Fclts	$34,800	DonatedServicesUseFcltsAmt
Expenses Not Reported	$34,800	ExpensesNotReportedAmt
Expenses Subtotal	$27,431,963	ExpensesSubtotalAmt
Investment Expenses Not Incld2	$239,987	InvestmentExpensesNotIncld2Amt
Expenses Not Rpt Fincl Stmt	$239,987	ExpensesNotRptFinclStmtAmt
Total Expenses Per Form990	$27,671,950	TotalExpensesPerForm990Amt

Supplemental Information Detail SupplementalInformationDetail (3 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
PART III, LINE 4:	COLLECTIONS OF ART, HISTORICAL TREASURES, OR OTHER SIMILIAR ASSETS AMFAR HOLDS VARIOUS ITEMS OF JEWELRY, PHOTOGRAPHS AND OTHER ITEMS OF ARTISTIC VALUE THAT HAVE BEEN DONATED TO THE ORGANIZATION FOR SALE AT SPECIAL EVENTS. THE ORGANIZATION HAS MAINTAINED THESE ITEMS IN INVENTORY FOR A FEW YEARS AND IS IN THE PROCESS OF SELLING THEM.
PART V, LINE 4:	ENDOWMENTS AMFAR'S ENDOWNMENT FUND IS INTENDED TO FUND THE VARIOUS GENERAL RESEARCH PROGRAMS THE ORGANIZATION SPONSORS.
PART X, LINE 2:	FIN 48 - INCOME TAXES AMFAR FOLLOWS GUIDANCE THAT CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN, INCLUDING ISSUES RELATING TO FINANCIAL STATEMENT RECOGNITION AND GUIDANCE ON MEASUREMENT. THIS GUIDANCE PROVIDES THAT THE TAX EFFECTS FROM AN UNCERTAIN TAX POSITION CAN ONLY BE RECOGNIZED IN THE FINANCIAL STATEMENTS IF THE POSITION IS "MORE-LIKELY-THAN-NOT" TO BE SUSTAINED IF THE POSITION WERE TO BE CHALLENGED BY A TAXING AUTHORITY. THE ASSESSMENT OF THE TAX POSITION IS BASED SOLELY ON THE TECHNICAL MERITS OF THE POSITION, WITHOUT REGARD TO THE LIKELIHOOD THAT THE TAX POSITION MAY BE CHALLENGED. AMFAR IS EXEMPT FROM FEDERAL INCOME TAX UNDER IRC SECTION 501(C)(3), THOUGH IT IS SUBJECT TO TAX ON INCOME UNRELATED TO ITS EXEMPT PURPOSE, UNLESS THAT INCOME IS OTHERWISE EXCLUDED BY THE CODE. AMFAR HAS PROCESSES PRESENTLY IN PLACE TO ENSURE THE MAINTENANCE OF ITS TAX-EXEMPT STATUS; TO IDENTIFY AND REPORT UNRELATED INCOME; TO DETERMINE ITS FILING AND TAX OBLIGATIONS IN JURISDICTIONS FOR WHICH IT WAS NEXUS; AND TO IDENTIFY AND EVALUATE OTHER MATTERS THAT MAY BE CONSIDERED TAX POSITIONS. AMFAR HAS DETERMINED THAT THERE ARE NO MATERIAL UNCERTAIN TAX POSITIONS THAT REQUIRE RECOGNITION OR DISCLOSURE IN THE FINANCIAL STATEMENTS.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Account Activities Outside US AccountActivitiesOutsideUSGrp (9 entries)

RegionRegionTxt	Type Of Activities ConductedTypeOfActivitiesConductedTxt	Specific Services ProvidedSpecificServicesProvidedTxt	Region Total ExpendituresRegionTotalExpendituresAmt	OfficesOfficesCnt	EmployeeEmployeeCnt
EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA,	GRANTMAKING	N/A	$1,646,778
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM	GRANTMAKING	N/A	$332,121
NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES	GRANTMAKING	N/A	$157,284
SOUTH AMERICA - ARGENTINA, BOLIVIA, BRAZIL, CHILE, COLUMBIA, ECUADOR,	GRANTMAKING	N/A	$21,014
SOUTH ASIA - AFGHANISTAN, BANGLADESH, BHUTAN, INDIA, MALDIVES, NEPAL,	GRANTMAKING	N/A	$174,653
SUB-SAHARAN AFRICA - ANGOLA, BENIN, BOTSWANA, BURKINA FASO,	GRANTMAKING	N/A	$23,259
EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA,	PROGRAM SERVICES	THERAPEUTICS RESEARCH, TRAINING	$1,553,055	1	14
EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM	FUNDRAISING	N/A	$7,660,034
SOUTH AMERICA - ARGENTINA, BOLIVIA, BRAZIL, CHILE, COLUMBIA, ECUADOR,	FUNDRAISING	N/A	$10,230

Field	Value	IRS element (for citing)
Subtotal Offices	1	SubtotalOfficesCnt
Subtotal Employees	14	SubtotalEmployeesCnt
Continuation Total Office	0	ContinuationTotalOfficeCnt
Continuation Total Employee	0	ContinuationTotalEmployeeCnt
Total Office	1	TotalOfficeCnt
Total Employee	14	TotalEmployeeCnt
Subtotal Spent	$11,568,198	SubtotalSpentAmt
Continuation Spent	$10,230	ContinuationSpentAmt
Total Spent	$11,578,428	TotalSpentAmt

Grants To Org Outside US GrantsToOrgOutsideUSGrp (79 entries)

RegionRegionTxt	Purpose Of GrantPurposeOfGrantTxt	Cash GrantCashGrantAmt	Manner Of Cash DisbursementMannerOfCashDisbursementTxt	Non Cash AssistanceNonCashAssistanceAmt
EAST ASIA AND THE PACIFIC	BASIC RESEARCH	$11,462	WIRE	$0
EAST ASIA AND THE PACIFIC	BASIC RESEARCH	$149,999	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$56,440	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$61,551	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$5,475	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,425	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$6,300	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$10,962	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,652	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$552,519	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$16,150	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$19,997	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$15,400	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$22,988	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$21,500	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$22,580	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$23,334	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$15,858	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$21,224	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$20,166	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$12,356	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$21,960	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$21,352	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$21,608	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$20,380	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$21,894	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$18,830	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$8,000	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$6,000	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$8,000	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$10,000	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$8,000	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,995	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$8,991	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$9,000	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$20,000	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$20,000	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,452	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$15,000	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$14,444	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$24,932	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$20,000	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,484	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$19,374	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$21,717	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$23,245	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$16,581	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,827	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$8,045	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$6,753	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$7,500	WIRE	$0
EAST ASIA AND THE PACIFIC	TREAT ASIA	$6,360	WIRE	$0
EUROPE (INCLUDING ICELAND & GREENLAND)	BASIC RESEARCH	$49,988	WIRE	$0
EUROPE (INCLUDING ICELAND & GREENLAND)	RESEARCH	$557,406	WIRE	$0
SOUTH AMERICA	BASIC RESEARCH	$21,014	WIRE	$0
SOUTH ASIA	TREAT ASIA	$92,384	WIRE	$0
SOUTH ASIA	TREAT ASIA	$6,500	WIRE	$0
SOUTH ASIA	TREAT ASIA	$20,790	WIRE	$0
SOUTH ASIA	TREAT ASIA	$20,000	WIRE	$0
SOUTH ASIA	TREAT ASIA	$19,085	WIRE	$0
SOUTH ASIA	TREAT ASIA	$7,500	WIRE	$0
SOUTH ASIA	TREAT ASIA	$7,479	WIRE	$0
SUB-SAHARAN AFRICA	BASIC RESEARCH	$12,501	WIRE	$0
SUB-SAHARAN AFRICA	BASIC RESEARCH	$12,351	WIRE	$0
SUB-SAHARAN AFRICA	BASIC RESEARCH	$12,501	WIRE	$0
NORTH AMERICA	BASIC RESEARCH	$157,284	WIRE	$0

Field	Value	IRS element (for citing)
Total501c3 Org	79	Total501c3OrgCnt
Transfer To Foreign Corp	0	TransferToForeignCorpInd
Interest In Foreign Trust	0	InterestInForeignTrustInd
Foreign Corp Ownership	0	ForeignCorpOwnershipInd
Passive Foreign Investmest Co	0	PassiveForeignInvestmestCoInd
Foreign Partnership	0	ForeignPartnershipInd
Boycott Countries	0	BoycottCountriesInd

Supplemental Information Detail SupplementalInformationDetail (2 entries)

Form And Line ReferenceFormAndLineReferenceDesc

ExplanationExplanationTxt

PART I, LINE 2:

FOREIGN ACTIVITIES INTERNATIONAL ORGANIZATIONS ARE RECOMMENDED FOR FUNDING BASED UPON THE RESULTS OF COMMUNITY-BASED PEER REVIEW AND/OR PROGRAM STAFF ASSESSMENT OF PROPOSAL MERIT AND ORGANIZATION CAPACITY TO UNDERTAKE PROPOSED PROJECTS THAT ARE CHARITABLE IN PURPOSE. PRE-AWARD DUE-DILIGENCE FOR NEW INTERNATIONAL GRANTEES INCLUDES REVIEW OF ORGANIZATION DOCUMENTS AND REGISTRATIONS TO VERIFY THAT THE ORGANIZATION OPERATES FOR A CHARITABLE PURPOSE AND THAT BASIC CAPACITY FOR PROJECT OVERSIGHT AND GOVERNANCE HAS BEEN ESTABLISHED. ALL INTERNATIONAL GRANTEES ARE REQUIRED TO REPORT SEMI-ANNUALLY ON PROJECT PROGRESS AND EXPENDITURES; CONTINUED REPORTING IS REQUIRED UNTIL SUCH TIME AS GRANT FUNDS ARE EXPENDED IN FULL. REPORTS ARE REVIEWED BY ADMINISTRATIVE AND PROGRAM STAFF. ADDITIONAL OVERSIGHT IS PROVIDED AS NECESSARY BY MEANS OF ONGOING, INFORMAL CONTACT WITH SITES REGARDING PROGRESS AND TECHNICAL ISSUES AND SITE VISITS WHERE FEASIBLE. INTERNATIONAL RESEARCH GRANT RECIPIENTS SUBMIT AN INTERIM AND A FINAL PROGRESS REPORTING ADDITION TO EXPENDITURES REPORTS DUE FOLLOWING THE ENDS OF THE 2ND, 3RD AND FINAL QUARTERS OF THE PERFORMANCE PERIOD. FOREIGN ACTIVITIES PART I, LINE 3, COLUMN D THE FOUNDATION FOR AIDS RESEARCH CONDUCTS MANY OF ITS GRANT-MAKING PROGRAM SERVICES (SEE PART III OF FORM 990) IN U.S. AND FOREIGN JURISDICTIONS. IN COLUMN D, THE ORGANIZATION HAS REPORTED THE BASIC PROGRAM THESE GRANTS SUPPORT; PLEASE REFER TO PART III FOR MORE INFORMATION ABOUT THESE PROGRAMS/INITIATIVES. FOREIGN ACTIVITIES - STATUS OF GRANTEES THE FOUNDATION FOR AIDS RESEARCH SUPPORTS MANY NON-U.S. ORGANIZATIONS IN THE FIGHT AGAINST AIDS AND HIV-RELATED DISEASES. FOR PURPOSES OF SCHEDULE F, PART II, LINE 2 - ALL 79 CHARITIES SUPPORTED ARE PRESUMED TO BE THE EQUIVALENT OF U.S. CHARITIES.

PART III ACCOUNTING METHOD:

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	Yes (X)	MailSolicitationsInd
Email Solicitations	Yes (X)	EmailSolicitationsInd
Phone Solicitations	Yes (X)	PhoneSolicitationsInd
Solicitation Of Non Govt Grants	Yes (X)	SolicitationOfNonGovtGrantsInd
Solicitation Of Govt Grants	Yes (X)	SolicitationOfGovtGrantsInd
Special Fundraising Events	Yes (X)	SpecialFundraisingEventsInd
Agrmt Prof Fundraising Acty	Yes (1)	AgrmtProfFundraisingActyInd

Fundraiser Activity Info FundraiserActivityInfoGrp (2 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	ActivityActivityTxt	Fundraiser Control Of FundsFundraiserControlOfFundsInd	Gross ReceiptsGrossReceiptsAmt	Retained By ContractorRetainedByContractorAmt	Net To OrganizationNetToOrganizationAmt
AAB PRODUCTIONS
64 ALLEN ST	NEW YORK	NY	10002	SPECIAL EVENT PRODUCTION	0	$9,550,856	$281,000	$9,269,856
SANKY COMMUNICATIONS INC
599 11TH AVE	NEW YORK	NY	10036	DIRECT MAIL DIRECT RESPONSE CONSULTING	0	$1,307,493	$287,834	$1,019,659

Field	Value	IRS element (for citing)
Total Gross Receipts	$10,858,349	TotalGrossReceiptsAmt
Total Retained By Contractors	$568,834	TotalRetainedByContractorsAmt
Total Net To Organization	$10,289,515	TotalNetToOrganizationAmt
Licensed States	AK	LicensedStatesCd
Licensed States	AL	LicensedStatesCd
Licensed States	AR	LicensedStatesCd
Licensed States	CA	LicensedStatesCd
Licensed States	CO	LicensedStatesCd
Licensed States	CT	LicensedStatesCd
Licensed States	DC	LicensedStatesCd
Licensed States	FL	LicensedStatesCd
Licensed States	GA	LicensedStatesCd
Licensed States	HI	LicensedStatesCd
Licensed States	IL	LicensedStatesCd
Licensed States	KS	LicensedStatesCd
Licensed States	KY	LicensedStatesCd
Licensed States	LA	LicensedStatesCd
Licensed States	ME	LicensedStatesCd
Licensed States	MD	LicensedStatesCd
Licensed States	MA	LicensedStatesCd
Licensed States	MI	LicensedStatesCd
Licensed States	MN	LicensedStatesCd
Licensed States	MS	LicensedStatesCd
Licensed States	MO	LicensedStatesCd
Licensed States	NV	LicensedStatesCd
Licensed States	NH	LicensedStatesCd
Licensed States	NJ	LicensedStatesCd
Licensed States	NM	LicensedStatesCd
Licensed States	NY	LicensedStatesCd
Licensed States	NC	LicensedStatesCd
Licensed States	ND	LicensedStatesCd
Licensed States	OH	LicensedStatesCd
Licensed States	OK	LicensedStatesCd
Licensed States	OR	LicensedStatesCd
Licensed States	PA	LicensedStatesCd
Licensed States	RI	LicensedStatesCd
Licensed States	SC	LicensedStatesCd
Licensed States	TN	LicensedStatesCd
Licensed States	UT	LicensedStatesCd
Licensed States	VA	LicensedStatesCd
Licensed States	WA	LicensedStatesCd
Licensed States	WV	LicensedStatesCd
Licensed States	WI	LicensedStatesCd

Fundraising Event Information FundraisingEventInformationGrp

Field	Value	IRS element (for citing)
Event1	CANNES	Event1Nm
Gross Receipts Event1	$8,128,605	GrossReceiptsEvent1Amt
Charitable Contri Event1	$7,909,105	CharitableContriEvent1Amt
Gross Revenue Event1	$219,500	GrossRevenueEvent1Amt
Rent Facility Costs Event1	$1,215,643	RentFacilityCostsEvent1Amt
Food And Beverage Event1	$567,492	FoodAndBeverageEvent1Amt
Entertainment Event1	$2,152,373	EntertainmentEvent1Amt
Other Direct Expenses Event1	$3,176,775	OtherDirectExpensesEvent1Amt
Event2	VENICE	Event2Nm
Gross Receipts Event2	$668,403	GrossReceiptsEvent2Amt
Charitable Contri Event2	$569,903	CharitableContriEvent2Amt
Gross Revenue Event2	$98,500	GrossRevenueEvent2Amt
Food And Beverage Event2	$88,216	FoodAndBeverageEvent2Amt
Entertainment Event2	$149,669	EntertainmentEvent2Amt
Other Direct Expenses Event2	$246,999	OtherDirectExpensesEvent2Amt
Other Events Total	12	OtherEventsTotalCnt
Gross Receipts Other Events	$1,406,485	GrossReceiptsOtherEventsAmt
Charitable Contri Other Events	$1,406,485	CharitableContriOtherEventsAmt
Food And Beverage Other Events	$3,914	FoodAndBeverageOtherEventsAmt
Entertainment Other Events	$41,095	EntertainmentOtherEventsAmt
Oth Direct Expnss Other Events	$68,898	OthDirectExpnssOtherEventsAmt
Gross Receipts Total	$10,203,493	GrossReceiptsTotalAmt
Charitable Contributions Tot	$9,885,493	CharitableContributionsTotAmt
Gross Revenue Total Events	$318,000	GrossRevenueTotalEventsAmt
Rent Fclty Costs Total Events	$1,215,643	RentFcltyCostsTotalEventsAmt
Food And Beverage Total Events	$659,622	FoodAndBeverageTotalEventsAmt
Entertainment Total Events	$2,343,137	EntertainmentTotalEventsAmt
Oth Direct Expnss Total Events	$3,492,672	OthDirectExpnssTotalEventsAmt
Direct Expense Summary Events	$7,711,074	DirectExpenseSummaryEventsAmt
Net Income Summary	-$7,393,074	NetIncomeSummaryAmt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	SCHEDULE G, PART I, LINE 2B, COLUMN (V)	FormAndLineReferenceDesc
Explanation	THE FOUNDATION FOR AIDS RESEARCH ACTUALLY PAID OUT $428,334 IN FUNDRAISING EXPENSES FOR THE YEAR ENDING SEPTEMBER 30, 2021. THIS AMOUNT IS REPORTED ON PART IX, LINE 11(E). FOR PURPOSES OF SCHEDULE G, THE FOUNDATION IS REPORTING ALL AMOUNTS PAID TO THE CONSULTANTS LISTED ON PART I, REGARDLESS OF WHETHER SUCH AMOUNTS WERE PURE FUNDRAISING EXPENSES OR EVENT PRODUCTION COSTS. ON SCHEDULE G, THE TOTAL AMOUNT PAID TO THE ORGANIZATIONS LISTED IS $568,834. OF THAT $568,834, ONLY $428,334 WAS PAID FOR FUNDRAISING SERVICES, THE REMAINING $140,500 WAS PAID FOR EVENT PRODUCTION SERVICES. IN THE INTERESTS OF CLARITY, THE FOUNDATION WOULD ALSO LIKE TO MAKE CLEAR THAT THE COMPENSATION REPORTED AS HAVING BEEN PAID TO THE PROFESSIONAL FUNDRAISERS REPORTED ON SCHEDULE G IS REPORTED ON A FISCAL YEAR BASIS. SOME OF THOSE SAME FUNDRAISERS ARE REPORTED ON THE FOUNDATION'S TOP 5 HIGHEST PAID INDEPENDENT CONTRACTORS LIST (IN PART VII). IN COMPLIANCE WITH THE INSTRUCTIONS TO THE FORM 990, COMPENSATION REPORTED FOR PART VII IS REPORTED ON A CALENDAR YEAR BASIS. ACCORDINGLY, AMOUNTS ON PART VII AND SCHEDULE G WILL NOT RECONCILE.	ExplanationTxt

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Grant Records Maintained	Yes (1)	GrantRecordsMaintainedInd

Recipient Table RecipientTable (22 entries)

Address Line1USAddress/AddressLine1Txt	CityUSAddress/CityNm	State AbbreviationUSAddress/StateAbbreviationCd	ZIPUSAddress/ZIPCd	Recipient EINRecipientEIN	IRC SectionIRCSectionDesc	Cash GrantCashGrantAmt	Purpose Of GrantPurposeOfGrantTxt
THE UNIVERSITY OF MICHIGAN
3003 SOUTH STATE STREET	ANN ARBOR	MI	48109	386006309	501(C)(3)	$116,738	BASIC RESEARCH
BETH ISRAEL DEACONESS MEDICAL CENTER
330 BROOKLINE AVENUE	BOSTON	MA	02215	042103881	501(C)(3)	$71,142	BASIC RESEARCH
MAYO CLINIC COLLEGE OF MEDICINE
200 FIRST STREET SW	ROCHESTER	MN	55905	416011702	501(C)(3)	$10,714	BASIC RESEARCH
OREGON HEALTH AND SCIENCE UNIVERSITY
3181 SW SAM JACKSON PARK ROAD	PORTLAND	OR	97239	931176109	501(C)(3)	$14,282	BASIC RESEARCH
FRED HUTCHINSON CANCER RESEARCH CENTER
1100 FAIRVIEW AVE N	SEATTLE	WA	98109	237156071	501(C)(3)	$14,136	BASIC RESEARCH
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY
1300 YORK AVENUE	NEW YORK	NY	10065	131623978	501(C)(3)	$150,000	BASIC RESEARCH
THE WISTAR INSTITUTE
3601 SPRUCE STREET	PHILADELPHIA	PA	19104	236434390	501(C)(3)	$37,916	BASIC RESEARCH
THE BRIGHAM AND WOMEN'S HOSPITAL INC
75 FRANCIS STREET	BOSTON	MA	02115	042312909	501(C)(3)	$304,710	BASIC RESEARCH
YALE UNIVERSITY
266 WHITNEY AVE	NEW HAVEN	CT	06511	060646973	501(C)(3)	$203,289	BASIC RESEARCH
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
3333 CALIFORNIA STREET SUITE 315	SAN FRANCISCO	CA	94143	946036493	501(C)(3)	$1,652,000	RESEARCH
JOHNS HOPKINS UNIVERSITY
733 N BROADWAY MRB SUITE 117	BALTIMORE	MD	21205	520595110	501(C)(3)	$593,360	RESEARCH/TREAT ASIA
COLUMBIA UNIVERSITY
630 WEST 168TH ST BOX 49	NEW YORK	NY	10032	135598093	501(C)(3)	$22,796	TREAT ASIA
MASSACHUSETTS GENERAL HOSPITAL
101 HUNTINGTON AVE SUITE 300	BOSTON	MA	02199	042697983	501(C)(3)	$109,947	BASIC RESEARCH
UNIVERSITY OF IOWA
451 NEWTON ROAD	IOWA CITY	IA	52242	426004813	501(C)(3)	$149,995	BASIC RESEARCH
GLADSTONE INSTITUTE
1650 OWENS STREET	SAN FRANCISCO	CA	94158	237203666	501(C)(3)	$50,000	BASIC RESEARCH
THE SCRIPPS RESEARCH INSTITUTE
10550 NORTH TORREY PINES ROAD	LA JOLLA	CA	92037	330435954	501(C)(3)	$50,000	BASIC RESEARCH
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER
11937 US HIGHWAY 271	TYLER	TX	75708	756001354	501(C)(3)	$20,001	BASIC RESEARCH
AIDS WALK SAN FRANCISCO FOUNDATION
273 NINTH STREET	SAN FRANCISCO	CA	94193	474861977	501(C)(3)	$7,500	PREVENTION SCIENCE OUTREACH
HEALTH GAP (GLOBAL ACCESS PROJECT)
81 PROSPECT STREET	BROOKLYN	NY	11201	205053765	501(C)(3)	$102,813	PUBLIC POLICY
NATIONAL HOSPITAL OF TROPICAL DISEASES
423 WEST 127 STREET 4TH FLOOR	NEW YORK	NY	10027	943240841	501(C)(3)	$52,826	PUBLIC POLICY
GLOBAL ACTION FOR TRANS EQUALITY GATE INC
576 5TH AVENUE	NEW YORK	NY	10036	371762577	501(C)(3)	$34,594	PUBLIC POLICY
UNIVERSITY OF CALIFORNIA LOS ANGELES
11000 KINROSS AVENUE SUITE 211	LOS ANGELES	CA	90095	956006143	501(C)(3)	$91,665	BASIC RESEARCH

Field	Value	IRS element (for citing)
Total501c3 Org	22	Total501c3OrgCnt

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINE 2:	FormAndLineReferenceDesc
Explanation	AMFAR PROVIDES GRANTS AND FELLOWSHIPS TO INDEPENDENT NOT-FOR-PROFIT ORGANIZATIONS THROUGH A PEER-REVIEW PROCESS. GRANT APPLICATIONS ARE FIRST REVIEWED BY THE FOUNDATION'S VOLUNTEER SCIENTIFIC ADVISORY COMMITTEE, WHICH COMPRISES RECOGNIZED EXPERTS IN THE MEDICAL, SCIENTIFIC, AND SOCIAL SCIENCES DISCIPLINES RELEVANT TO HIV AND AIDS. THE SCIENTIFIC ADVISORY COMMITTEE THEN SENDS ITS EVALUATIONS TO ONE OF THE THREE COMMITTEES (RESEARCH, GLOBAL INITIATIVES OR PUBLIC POLICY) OF THE FOUNDATION'S PROGRAM BOARD, WHICH SERVES IN AN ADVISORY CAPACITY TO THE BOARD OF TRUSTEES. AFTER A PROGRAM COMMITTEE HAS COMPLETED ITS REVIEW OF THE APPLICATIONS, IT PRESENTS ITS FUNDING RECOMMENDATIONS TO AMFAR'S EXECUTIVE COMMITTEE AND/OR THE FULL BOARD OF TRUSTEES FOR FINAL APPROVAL AND FUNDING AUTHORIZATION. GRANTS AND FELLOWSHIPS ARE PAYABLE OVER A ONE-TO-THREE-YEAR PERIOD, AND ARE REVOCABLE AT AMFAR'S OPTION IF THE RECIPIENT'S PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH THE TERMS OF THE GRANT OR FELLOWSHIPS. IN CERTAIN CASES, THE ACTUAL AMOUNTS PAID UNDER GRANTS AND FELLOWSHIP AWARDS MAY BE LESS THAN THE ORIGINAL AWARD IF THE RECIPIENT DOES NOT USE THE FULL AMOUNT AWARDED. THEREFORE, A RESERVE FOR UNEXPENDED GRANTS AND FELLOWSHIPS HAS BEEN RECORDED. SUBAWARDS ARE GRANTS AWARDED TO NOT-FOR-PROFIT ORGANIZATIONS TO SUPPORT THE COSTS OF COLLABORATION AND PARTICIPATION IN HIV/AIDS-RELATED RESEARCH PROJECTS FOR WHICH AMFAR HAS SECURED RESTRICTED FUNDS. SUBAWARDS ARE PAYABLE OVER A ONE-YEAR PERIOD, ALTHOUGH ADVANCE PAYMENTS, IN FULL OR IN PART, MAY BE ISSUED FOLLOWING EXECUTION OF THE SUBAWARD AGREEMENT. SUBAWARDS ARE CONTINGENT UPON THE AVAILABILITY OF FUNDS AND ARE REVOCABLE IF THE RECIPIENTS' PERFORMANCE OR USE OF FUNDS IS NOT CONSISTENT WITH THE SUBAWARD TERMS.	ExplanationTxt

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	Yes (X)	CompensationCommitteeInd
Independent Consultant	Yes (X)	IndependentConsultantInd
Compensation Survey	Yes (X)	CompensationSurveyInd
Board Or Committee Approval	Yes (X)	BoardOrCommitteeApprovalInd
Severance Payment	Yes (1)	SeverancePaymentInd
Supplemental Nonqual Rtr Plan	Yes (1)	SupplementalNonqualRtrPlanInd
Equity Based Comp Arrngm	0	EquityBasedCompArrngmInd
Comp Based On Revenue Of Flng Org	0	CompBasedOnRevenueOfFlngOrgInd
Comp Bsd On Rev Related Orgs	0	CompBsdOnRevRelatedOrgsInd
Comp Bsd Net Earns Flng Org	0	CompBsdNetEarnsFlngOrgInd
Comp Bsd Net Earns Rltd Orgs	0	CompBsdNetEarnsRltdOrgsInd
Any Non Fixed Payments	0	AnyNonFixedPaymentsInd
Initial Contract Exception	0	InitialContractExceptionInd

Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (14 entries)

TitleTitleTxt	Base Compensation Filing OrgBaseCompensationFilingOrgAmt	Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt	Bonus Filing OrganizationBonusFilingOrganizationAmount	Bonus Related OrganizationsBonusRelatedOrganizationsAmt	Other Compensation Filing OrgOtherCompensationFilingOrgAmt	Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt	Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt	Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt	Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt	Total Compensation Filing OrgTotalCompensationFilingOrgAmt	Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt	Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt
KEVIN FROST
CHIEF EXECUTIVE OFFICER	$445,488	$0	$0	$0	$42,155	$0	$39,450	$0	$62,087	$0	$589,180	$0	$0	$0
BRADLEY JENSEN
ASSISTANT TREASURER/CFO	$267,465	$0	$0	$0	$0	$0	$19,875	$0	$47,934	$0	$335,274	$0	$0	$0
ANNMARIE SHANNAHAN
VICE PRESIDENT, PUBLIC INFO	$241,584	$0	$0	$0	$0	$0	$17,396	$0	$47,934	$0	$306,914	$0	$0	$0
ANNETTE SOHN
VICE PRESIDENT, TREAT ASIA	$254,537	$0	$0	$0	$0	$0	$18,093	$0	$8,339	$0	$280,969	$0	$0	$0
ANTHONY ANCONA
VICE PRESIDENT, HR	$194,456	$0	$0	$0	$0	$0	$14,050	$0	$47,934	$0	$256,440	$0	$0	$0
ANDREW MCINNESS
DIRECTOR, PUBLICATIONS	$173,945	$0	$0	$0	$0	$0	$12,689	$0	$62,087	$0	$248,721	$0	$0	$0
GREGORIO MILLET
VICE PRESIDENT, PUBLIC POLICY	$186,031	$0	$0	$0	$0	$0	$14,679	$0	$47,934	$0	$248,644	$0	$0	$0
JONATHAN KEY THRU 101320
DIRECTOR, PHILANTHROPY	$165,687	$0	$0	$0	$59,525	$0	$4,107	$0	$19,177	$0	$248,496	$0	$0	$0
SEBASTIAN GHEITH
ASSOCIATE COUNSEL, ASST SECRETARY	$172,886	$0	$0	$0	$0	$0	$12,683	$0	$62,087	$0	$247,656	$0	$0	$0
ROWENA JOHNSTON
ASST SEC, VP, RESEARCH	$211,292	$0	$0	$0	$0	$0	$15,079	$0	$20,151	$0	$246,522	$0	$0	$0
BENNAH SERFATY
SENIOR DIRECTOR OF COMMUNICATIONS	$136,970	$0	$0	$0	$0	$0	$10,086	$0	$62,087	$0	$209,143	$0	$0	$0
EDWARD DONNELLY
ASST TREASURER, CONTROLLER	$170,841	$0	$0	$0	$0	$0	$12,495	$0	$18,442	$0	$201,778	$0	$0	$0
ERIC MUSCATELL THRU 073120
VICE PRESIDENT OF DEVELOPMENT	$155,651	$0	$0	$0	$0	$0	$16,474	$0	$19,177	$0	$191,302	$0	$0	$0
SUE DOSTER
CHIEF TECHNOLOGY OFFICER	$157,903	$0	$0	$0	$0	$0	$11,468	$0	$20,151	$0	$189,522	$0	$0	$0

Supplemental Information Detail SupplementalInformationDetail

Field	Value	IRS element (for citing)
Form And Line Reference	PART I, LINES 4A-B	FormAndLineReferenceDesc
Explanation	COMPENSATION DIRECTOR OF PHILANTHROPY, JONATHAN KEY, RECEIVED A SEVERANCE PAYMENT OF $59,525 IN CALENDAR YEAR 2021; THIS SEVERANCE IS REPORTED IN FORM 990, SCHEDULE J, PART II, COLUMN (B)(III). CHIEF EXECUTIVE OFFICER, KEVIN FROST, PARTICIPATED IN A SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN. IN CALENDAR YEAR 2021, AMFAR CONTRIBUTED $42,155 INTO MR. FROST'S NON-QUALIFIED RETIREMENT PLAN. THIS AMOUNT IS NOT REPORTED IN SCHEDULE J, PART II, COLUMN (C) BECAUSE THE CONTRIBUTED AMOUNT WAS DISTRIBUTED TO MR. FROST WITHIN THE SAME CALENDAR YEAR. INCLUDED IN SCHEDULE J COLUMN (B)(III) IS MR. FROST'S 2021 EMPLOYER-FUNDED 457(F) CONTRIBUTION OF $42,155.	ExplanationTxt

Schedule M IRS990ScheduleM

Securities Publicly Traded SecuritiesPubliclyTradedGrp

Field	Value	IRS element (for citing)
Non Cash Checkbox	Yes (X)	NonCashCheckboxInd
Contribution	7	ContributionCnt
Noncash Contributions Rpt F990	$217,327	NoncashContributionsRptF990Amt
Method Of Determining Revenues	FMV	MethodOfDeterminingRevenuesTxt

Field	Value	IRS element (for citing)
Any Property That Must Be Held	0	AnyPropertyThatMustBeHeldInd
Review Process Unusual NC Gifts	0	ReviewProcessUnusualNCGiftsInd
Third Parties Used	0	ThirdPartiesUsedInd

Schedule O IRS990ScheduleO

Supplemental Information Detail SupplementalInformationDetail (9 entries)

Form And Line ReferenceFormAndLineReferenceDesc	ExplanationExplanationTxt
IMPACT OF COVID-19	THE EMERGENCE AND RAPID SPREAD OF COVID-19 ACROSS THE UNITED STATES IN EARLY 2020 HAS IMPACTED WORLDWIDE ECONOMIC ACTIVITY AND FINANCIAL MARKETS, HAD AN IMMEDIATE, SUBSTANTIAL AND SUSTAINED IMPACT ON AMFAR'S OPERATIONAL AND FUNDRAISING CAPACITY. WITH FUNDRAISING PERFORMANCE TIED IN LARGE PART TO AMFAR'S ABILITY TO ORCHESTRATE AND EXECUTE BENEFIT GALAS ACROSS THE U.S. AND AROUND THE WORLD, THE CORONAVIRUS LOCKDOWN AND STRICT LIMITATIONS ON INTERNATIONAL TRAVEL AND CONGREGATE EVENTS BROUGHT THIS REVENUE STREAM TO A HALT ALMOST OVERNIGHT. SINCE THE SPRING OF 2020, ALL LIVE FUNDRAISING EVENTS HAVE BEEN SUSPENDED, ALL NONESSENTIAL EXPENSES HAVE BEEN ELIMINATED, AND AMFAR HAS BEEN DEPENDENT ON ITS FINANCIAL RESERVES. THE FOUNDATION REMAINS IN A HOLDING PATTERN UNTIL SUCH TIME AS WIDESPREAD VACCINE DISTRIBUTION HAS CONTROLLED THE PANDEMIC TO THE EXTENT THAT UNFETTERED INTERNATIONAL TRAVEL AND LARGE GATHERINGS OF PEOPLE CAN RESUME. MANAGEMENT HAS CONSIDERED THE CONSEQUENCES OF COVID AND DETERMINED THAT THERE IS NO CURRENT MATERIAL UNCERTAINTY IDENTIFIED THAT WOULD AFFECT ITS ABILITY TO CONTINUE ITS MISSION TO END THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. HOWEVER, THERE IS SIGNIFICANT UNCERTAINTY AROUND THE BREADTH AND DURATION OF BUSINESS DISRUPTIONS RELATED TO COVID, AS WELL AS ITS IMPACT ON THE U.S. AND INTERNATIONAL ECONOMIES AND, AS SUCH, THE FOUNDATION IS UNABLE TO DETERMINE IF IT WILL HAVE A FUTURE MATERIAL NEGATIVE IMPACT ON ITS OPERATIONS OR FINANCIAL CONDITION. ON MAY 6, 2020, AMFAR WAS GRANTED A LOAN IN AGGREGATE AMOUNT OF $1,643,364 PURSUANT TO THE SMALL BUSINESS ADMINISTRATION PAYCHECK PROTECTION PROGRAM (THE "PPP") UNDER DIVISION A, TITLE 1 OF THE CARES ACT (THE "PPP LOAN"). THE PPP LOAN, WHICH WAS IN THE FORM OF A NOTE DATED MAY 1, 2020, MATURES ON MAY 6, 2022 AND BEARS INTEREST AT A RATE OF 1% PER ANNUM. THE PPP LOAN MAY BE PREPAID BY AMFAR AT ANY TIME PRIOR TO MATURITY WITH NO REPAYMENT PENALTIES. FUNDS FROM THE PPP LOAN MAY ONLY BE USED FOR CERTAIN COSTS, SUCH AS PAYROLL COSTS AND OCCUPANCY EXPENSES. THE LOAN AND ACCRUED INTEREST ARE FORGIVABLE AS LONG AS THE BORROWER USES THE LOAN PROCEEDS AS DESCRIBED IN THE CARES ACT. ON FEBRUARY 22, 2021, AMFAR WAS GRANTED A SECOND DRAW PPP LOAN IN AGGREGATE AMOUNT OF $ 1,677,930 PURSUANT TO THE SMALL BUSINESS ADMINISTRATION PAYCHECK PROTECTION PROGRAM (THE "PPP") UNDER DIVISION A, TITLE 1 OF THE CARES ACT (THE "PPP LOAN"). AMFAR USED THE BOTH PPP LOANS FOR QUALIFYING EXPENSES AS OF SEPTEMBER 30, 2021, AS DESCRIBED IN THE CARES ACT AND THE LOANS WERE FORGIVEN. THE PPP LOANS ARE REPORTED AS GOVERNMENTAL GRANT REVENUE ON THE CURRENT YEAR FORM 990 IN PART VIII, LINE 1(E).
FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION:	THE FOUNDATION FOR AIDS RESEARCH IS AN INTERNATIONAL NOT-FOR-PROFIT ORGANIZATION INCORPORATED IN NEW YORK IN 1989. AMFAR WAS FORMED THROUGH THE UNIFICATION IN 1985 OF TWO NOT-FOR-PROFIT ORGANIZATIONS, THE AIDS MEDICAL FOUNDATION ("AMF"), INCORPORATED IN NEW YORK IN APRIL 1983, AND THE NATIONAL AIDS RESEARCH FOUNDATION, INCORPORATED IN CALIFORNIA IN AUGUST 1985. FIRST BASED IN CALIFORNIA, AMFAR TRANSFERRED ITS LEGAL DOMICILE TO NEW YORK IN 1989, USING THE INITIAL INCORPORATION DOCUMENTS OF AMF, MAKING IT AMF'S LEGAL SUCCESSOR. AMFAR HAS OFFICES IN NEW YORK, NY, WASHINGTON, D.C., AND BANGKOK, THAILAND. ON MARCH 7, 2005, THE BOARD OF TRUSTEES OF THE AMERICAN FOUNDATION FOR AIDS RESEARCH APPROVED A CHANGE IN LEGAL NAME TO "THE FOUNDATION FOR AIDS RESEARCH." ON OCTOBER 18, 2005, THE NEW YORK STATE DEPARTMENT OF STATE APPROVED THIS CHANGE. IN ADDITION, THE FOUNDATION HAS SECURED APPROVAL FOR DOING BUSINESS AS (DBA) THE FOLLOWING: - AMERICAN FOUNDATION FOR AIDS RESEARCH - AMFAR - AIDS RESEARCH FOUNDATION AMFAR IS DEDICATED TO ENDING THE GLOBAL AIDS EPIDEMIC THROUGH INNOVATIVE RESEARCH. THE FOUNDATION ACCOMPLISHES THIS MISSION THROUGH: RESEARCH TO EXPLORE SCIENTIFIC APPROACHES TO HIV PREVENTION, TREATMENT, AND POTENTIAL CURES, AND TO ENHANCE THE HEALTH AND SURVIVAL OF PEOPLE LIVING WITH HIV/AIDS; - INTERNATIONAL INITIATIVES TO FACILITATE THE DEVELOPMENT AND IMPLEMENTATION OF EFFECTIVE RESEARCH, TREATMENT, PREVENTION, AND EDUCATION STRATEGIES IN LOW- AND MIDDLE-INCOME COUNTRIES; - PUBLIC POLICY ANALYSIS AND THE ADVOCACY OF RATIONAL AND COMPASSIONATE POLICIES THAT PROMOTE PUBLIC HEALTH AND PROTECT THE RIGHTS OF PEOPLE THREATENED BY HIV/AIDS; - EDUCATIONAL INITIATIVES TO BUILD AWARENESS OF THE CONTINUED THREAT HIV/AIDS POSES AND TO PUBLISH UPDATES ABOUT THE LATEST MEDICAL, SCIENTIFIC, AND PREVENTION ADVANCES FOR PEOPLE LIVING WITH HIV/AIDS, HEALTHCARE PROFESSIONALS, AND THE PUBLIC.
FORM 990, PART III, LINE 4A	COVID-19 GRANTS EXPANDING ITS EFFORTS TO INCLUDE RESEARCH ON THE NOVEL CORONAVIRUS, IN APRIL 2020 AMFAR ESTABLISHED THE AMFAR FUND TO FIGHT COVID-19. IN JULY 2021 AMFAR AWARDED APPROXIMATELY $700,000 TO RESEARCHERS TRYING TO ANSWER TWO KEY QUESTIONS AT THE INTERSECTION OF HIV AND COVID-19. WHAT ARE THE RISKS FOR COVID "LONG-HAULERS" (THOSE WHO CONTINUE TO EXPERIENCE DEBILITATING SYMPTOMS LONG AFTER CLEARING INFECTION) WHO ARE LIVING WITH HIV? A RECENT STUDY IN THE UK SUGGESTS THAT AS MANY AS 10% OF PEOPLE DIAGNOSED WITH COVID-19 EXPERIENCE SYMPTOMS FOR THREE MONTHS OR MORE AFTER CONTRACTING THE INFECTION. BUT LITTLE IS KNOWN ABOUT LONG COVID BEYOND THE FACT THAT COMMON SYMPTOMS SUCH AS PERSISTENT FATIGUE, MUSCLE WEAKNESS, BRAIN FOG, SLEEP DIFFICULTIES, ANXIETY AND DEPRESSION CAN BE EXTREMELY DEBILITATING. DR. ANNUKKA ANTAR OF JOHNS HOPKINS UNIVERSITY, AND DR. MICHAEL PELUSO OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, PLAN TO COMPARE THIS PHENOMENON ACROSS THREE GROUPS OF STUDY PARTICIPANTS FROM ACROSS THE U.S. IN THE STUDY, PWH WHO HAVE SURVIVED COVID-19 ARE COMPARED TO PWH WITH NO HISTORY OF COVID AND SURVIVORS WHO ARE HIV-NEGATIVE. USING A MOBILE PHLEBOTOMY SERVICE, DRS. ANTAR AND PELUSO ALSO PLAN TO COLLECT BLOOD SAMPLES AND STUDY VITAL SIGNS TO AID IN UNDERSTANDING THE BIOLOGICAL UNDERPINNINGS OF LONG-TERM COVID. WHAT, IF ANY, EFFECT DOES SARS-COV-2 HAVE ON THE HIV RESERVOIR? THE STRONG IMMUNE RESPONSES ASSOCIATED WITH CORONAVIRUS INFECTION MAY IMPACT THE SIZE OF THE HIV RESERVOIR. THIS DEPENDS ON HOW THESE IMMUNE RESPONSES AFFECT T CELLS, THE MAIN TARGET OF HIV INFECTION, AND THE EFFECTIVENESS OF ANTIRETROVIRAL THERAPY AT PREVENTING INFECTION OF PREVIOUSLY UNINFECTED CELLS. DR. MATHIAS LICHTERFELD, OF MASSACHUSETTS GENERAL HOSPITAL, AND COLLEAGUES AIM TO ASSESS THE SIZE AND NATURE OF THE RESERVOIR IN PWH BEFORE AND AFTER CORONAVIRUS INFECTION. THE RESEARCHERS ARE COMPARING THE PERCENTAGE OF CELLS THAT ARE HIV-INFECTED WITH SAMPLES STORED BEFORE THE COVID-19 PANDEMIC. THEY ARE ALSO LOOKING FOR ANY EFFECT OF THE SITE OF HIV INTEGRATION WITHIN THE HUMAN DNA ON RESERVOIR SIZE AND ASSESSING THE LIKELIHOOD OF ACTIVATION BY COVID-ASSOCIATED IMMUNE RESPONSES. UNDERSTANDING THESE CHANGES WILL HELP INFORM FUTURE HIV CURATIVE INTERVENTIONS. MATHILDE KRIM FELLOWSHIPS THE RECIPIENTS OF THE 2021 MATHILDE KRIM FELLOWSHIPS IN BIOMEDICAL RESEARCHDR. ALEKSANDAR ANTANASIJEVIC OF THE SCRIPPS RESEARCH INSTITUTE, LA JOLLA, CA, AND DR. UJJWAL RATHORE OF THE GLADSTONE INSTITUTES, SAN FRANCISCO, CAWERE ANNOUNCED IN MARCH 2021. DR. ANTANASIJEVIC IS USING A SOPHISTICATED IMAGING TECHNOLOGY CALLED CRYOEMPEM TO ADDRESS THE OBSTACLES THAT MAKE DEVELOPING AN HIV VACCINE SO CHALLENGING. USING A NEWLY DEVELOPED CRISPR-CAS9 GENE-EDITING SYSTEM, DR. RATHORE'S RESEARCH SEEKS TO UNDERSTAND HOW HUMAN CELLS HELP MAINTAIN HIV LATENCY, A MAIN BARRIER TO A CURE. EACH FELLOW IS AWARDED APPROXIMATELY $150,000 OVER TWO YEARS. KRIM FELLOW DR. MAOLIN LU, OF UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT TYLER, WAS AWARDED A SECOND PHASE GRANT OF $80,000 IN JUNE 2021. DR. LU IS A STRUCTURAL BIOLOGIST AND EXPERT IN THE USE OF STATE-OF-THE-ART IMAGING TECHNIQUES. SHORTLY BEFORE RECEIVING A KRIM FELLOWSHIP IN 2019, DR. LU PUBLISHED A GROUNDBREAKING STUDY IN NATURE THAT UPENDED THE HIV VACCINE FIELD. DR. LU'S AMFAR-FUNDED STUDY BUILT ON HER OWN GROUNDBREAKING RESEARCH. PUBLISHED RESEARCH RESEARCH STUDIES MAKE THE GREATEST IMPACT ON THE HIV FIELD AND ON THE BROADER SCIENTIFIC COMMUNITY WHEN THEY ARE PUBLISHED IN SCIENTIFIC JOURNALS. IN FY2021, 45 SCIENTIFIC PUBLICATIONS RESULTED FROM AMFAR-FUNDED RESEARCH. EXAMPLES INCLUDE: PREDICTING POST-TREATMENT CONTROL OF HIV FINDING A BIOMARKER THAT CAN PREDICT THE LIKELIHOOD OF HIV REMISSION AFTER THE CESSATION OF TREATMENT IS A KEY BARRIER TO ERADICATING HIV. WITH THE HELP OF MACHINE-LEARNING TOOLS, AMFAR-FUNDED RESEARCHERS LED BY DR. MOHAMED ABDEL-MOHSEN DEVELOPED BLOOD-BASED BIOMARKERS THAT WERE ABLE TO PREDICT THE PROBABILITY OF VIRAL REBOUND WITH ALMOST 98% ACCURACY. THE STUDY, PUBLISHED IN THE INFLUENTIAL JOURNAL NATURE COMMUNICATIONS, COULD HELP FILL A CRITICAL GAP IN THE HIV CURE RESEARCH FIELD. CAR T CELLS FOR HIV CURE CAR T CELLS HAVE REVOLUTIONIZED THE TREATMENT OF CERTAIN LEUKEMIAS AND LYMPHOMAS. AMFAR GRANTEES DRS. SCOTT KITCHEN AND JEROME ZACK OVERCAME TWO MAJOR CHALLENGES TO THE USE OF THIS THERAPY TO KILL RESERVOIR CELLS AND CURE HIV. AS DESCRIBED IN PLOS PATHOGENS, THEY GENE-EDITED STEM CELLS TO IMPROVE THE LONG-TERM SURVIVAL OF THE RESULTING CAR T CELLS AND USED A GENE MODIFICATION THAT NOT ONLY PROTECTS THE CELLS FROM HIV INFECTION, BUT ALSO IMPROVES THEIR CONVERSION FROM STEM CELLS TO CAR T CELLS. THE RESEARCHERS ALSO REPORTED IN JCI INSIGHT THAT THESE CELLS TRAFFIC TO TISSUE REGIONS WHERE RESERVOIRS ARE MOST CONCENTRATED. MEET THE SCIENTISTS IN HONOR OF WORLD AIDS DAY, IN DECEMBER 2020 AMFAR HELD A VIRTUAL CONVENING OF MEET THE SCIENTISTS. VICE PRESIDENT AND DIRECTOR OF RESEARCH, DR. ROWENA JOHNSTON, MODERATED A STIMULATING DISCUSSION WITH AMFAR GRANTEES DR. TIMOTHY SCHACKER OF THE UNIVERSITY OF MINNESOTA MEDICAL SCHOOL AND DR. JEROME ZACK OF THE UNIVERSITY OF CALIFORNIA, LOS ANGELES. THE EVENT FOCUSED ON STATE-OF-THE-ART RESEARCH ON NATURAL KILLER (NK) CELLS, THE SUBJECT OF GROWING INTEREST AS PART OF A CURE FOR HIV. DR. SCHACKER COMPLETED AN AMFAR PROJECT EXPLORING TRANSPLANTATION OF NK CELLS BETWEEN CLOSE RELATIVES AS A MEANS OF REDUCING THE RESERVOIR IN THE HIV-POSITIVE RECIPIENT. AND AMFAR RECENTLY AWARDED FUNDING TO DR. ZACK, WHO IS COMPARING THE ABILITY OF NORMAL VERSUS ENGINEERED NK CELLS TO ELIMINATE CELLS HARBORING RESERVOIR VIRUS FROM THE BODY (SEE ABOVE).
FORM 990, PART III, LINE 4E OTHER PROGRAM SERVICE ACCOMPLISHMENTS	PUBLIC POLICY: INFORMED BY THOROUGH RESEARCH AND ANALYSIS, AMFAR IS A HIGHLY RESPECTED ADVOCATE OF RATIONAL AND COMPASSIONATE HIV/AIDS-RELATED PUBLIC POLICY. THE FOUNDATION IS ENGAGED IN EFFORTS TO SECURE NECESSARY INCREASES IN FUNDING FOR HIV/AIDS RESEARCH AND GLOBAL HIV/AIDS PROGRAMS, EXPAND ACCESS TO TREATMENT AND CARE FOR MARGINALIZED POPULATIONS, ADVOCATE HARM REDUCTION POLICIES AIMED AT REDUCING THE TRANSMISSION OF HIV AND HEPATITIS C (HCV) AMONG PEOPLE WHO INJECT DRUGS, AND PROTECT THE CIVIL RIGHTS OF ALL PEOPLE AFFECTED BY OR VULNERABLE TO HIV/AIDS. ENDING THE HIV EPIDEMIC IN THE U.S. THROUGHOUT THE YEAR, THE AMFAR POLICY TEAM WORKED CLOSELY WITH MEMBERS OF THE BIDEN ADMINISTRATION, THE CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), NATIONAL INSTITUTES OF HEALTH (NIH), AND THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) TO PROMOTE AN EVIDENCED-BASED RESPONSE TO THE U.S. HIV EPIDEMIC. THIS INCLUDED MULTIPLE ADVOCACY MEETINGS, COLLABORATIVE EVENTS, AND CONSULTATIONS, AS WELL AS ADVOCACY TO REESTABLISH THE WHITE HOUSE OFFICE OF NATIONAL AIDS POLICY. POLICY STAFF WERE INVITED TO DELIVER A PRESENTATION TO THE PRESIDENTIAL ADVISORY COUNCIL ON HIV/AIDS AND WORKED WITH OTHER DOMESTIC ADVOCATES TO DISCUSS RECOGNITION OF THE 40TH ANNIVERSARY OF THE HIV PANDEMIC WITH THE BIDEN ADMINISTRATION. AMFAR VICE PRESIDENT AND DIRECTOR OF PUBLIC POLICY GREG MILLETT TOOK PART IN A VIRTUAL WEBINAR AND CONVERSATION WITH SENIOR FEDERAL OFFICIALS AND COMMUNITY LEADERS ON THE 40TH ANNIVERSARY OF THE FIRST REPORTS OF HIV/AIDS ON TUESDAY, JUNE 15, 2021. AMFAR'S POLICY OFFICE WORKED TO SECURE $200 MILLION IN ADDITIONAL FUNDING ABOVE THE LEVEL OF THE PRESIDENT'S BUDGET REQUEST FOR HIV RESEARCH AT THE NIH IN THE FY2022 HOUSE APPROPRIATIONS BILL. POLICY STAFF WORKED CLOSELY WITH THE CDC AND COMMUNITY EDUCATION GROUP TO CO-HOST A MEETING ON SYNDEMICS AND THE HIV RESPONSE. POLICY STAFF ALSO PARTICIPATED AND PROVIDED KEY INSIGHTS IN THE 2021 CDC POLICY LEADERS WORKING GROUP FOR STATE POLICY PRIORITIES. THE POLICY OFFICE ALSO ENGAGED WITH THE DEVELOPMENT AND ROLLOUT OF THE UPDATED NATIONAL HIV/AIDS STRATEGY, INCLUDING DISCUSSIONS WITH THE WHITE HOUSE, AND AMFAR'S POLICY ANALYSES WERE CITED IN THE NEWLY RELEASED STRATEGY. THE COVID-19 PANDEMIC IN 2021, AMFAR CONTINUED TO HIGHLIGHT THE IMPACT OF COVID-19 ON THE HIV RESPONSE BOTH DOMESTICALLY AND GLOBALLY, AND THE INEQUITABLE DOMESTIC IMPACT OF COVID-19. POLICY STAFF PARTICIPATED IN THE COVID-19 HEALTH EQUITY TASK FORCE STAKEHOLDER BRIEFINGS WITH THE OFFICE OF PUBLIC ENGAGEMENT AND IN SEVERAL MEETINGS OF THE NIH COVID PREVENTION TRIALS NETWORK TO DISCUSS VACCINE DISTRIBUTION. POLICY STAFF DISCUSSED COVID-19 DATA DEFICIENCIES AND RECOMMENDATIONS FOR THE NEW ADMINISTRATION WITH OUR PARTNERS, AND DELIVERED PRESENTATIONS ON THE INTERSECTIONS OF COVID-19 WITH HIV, LGBT COMMUNITIES, AND RACIAL DISPARITIES. HIV AND THE OPIOID EPIDEMIC AMFAR MAINTAINS AN IMPORTANT AND WIDELY USED RESOURCE ON HIV AND THE OPIOID EPIDEMIC. ITS OPIOID & HEATH INDICATORS DATABASE (OPIOID.AMFAR.ORG) IS A FREE WEB PLATFORM DESIGNED TO SUPPORT LAWMAKERS, COMMUNITIES, AND ADVOCATES IN MAKING INFORMED DECISIONS ABOUT THE OPIOID EPIDEMIC AND ITS IMPACT ON HIV AND HEPATITIS C. THE SITE IS A WINDOW INTO THE OPIOID EPIDEMIC UNFOLDING IN EVERY AMERICAN'S BACKYARD. IT PROVIDES LOCAL TO NATIONAL STATISTICS USING RELIABLE DATA SOURCES ON NEW HIV AND HEPATITIS C INFECTIONS, OPIOID USE AND OVERDOSE DEATH RATES, AND THE AVAILABILITY OF SERVICES LIKE DRUG TREATMENT PROGRAMS AND SYRINGE EXCHANGE SERVICES. IN 2021 AMFAR STAFF WORKED WITH HHS ON THE ENDING THE HIV EPIDEMIC PLAN AND OPIOID AND INFECTIOUS DISEASE PROGRAMS. POLICY STAFF ALSO PARTICIPATED IN SAMHSA'S REGION 5 OPIOID TASKFORCE. GLOBAL HEALTH THE AMFAR POLICY OFFICE MAINTAINS AN ACTIVE ROLE IN GLOBAL ADVOCACY AND POLICY INITIATIVES INCLUDING ATTENDING PEPFAR COUNTRY OPERATIONAL PLANNING MEETINGS, THE GLOBAL FUND PARTNERSHIP FORUM, AND THE UN HIGH-LEVEL MEETINGS ON HIV/AIDS. POLICY STAFF ENGAGE IN ADVOCACY WITH HOUSE AND SENATE APPROPRIATIONS COMMITTEES TO SECURE STRONG GLOBAL HIV BUDGETS AND CLOSELY TRACK AND RESPOND TO NEW GLOBAL HEALTH POLICIES. ADDITIONALLY, THE POLICY OFFICE PLAYS A KEY ROLE AS A TECHNICAL ASSISTANCE PROVIDER FOR IN-COUNTRY COMMUNITY-LED MONITORING EFFORTS IN SEVEN COUNTRIES. IN THIS ROLE, AMFAR ENGAGES WITH LOCAL ACTIVISTS AND DATA COLLECTION TEAMS TO ENSURE HIGH-QUALITY DATA ARE PRODUCED FOR HIV SERVICE QUALITY MONITORING AND ADVOCACY WITH DUTY BEARERS. THROUGHOUT 2021 AMFAR STAFF PUBLISHED SEVERAL STUDIES IN ACADEMIC JOURNALS WITH FAR-REACHING POLICY IMPLICATIONS. IN MARCH 2021, AMFAR STAFF PUBLISHED THE ROLE OF CONTRACEPTION IN PREVENTING HIV-POSITIVE BIRTHS: GLOBAL ESTIMATES AND PROJECTIONS IN BMC PUBLIC HEALTH. THIS RESEARCH QUANTIFIES THE IMPORTANCE OF CONTRACEPTION FOR HIV PREVENTION AND HAS BEEN USED FOR GLOBAL ADVOCACY ON HIV/FAMILY PLANNING INTEGRATION. IN JUNE 2021, POLICY STAFF PUBLISHED CURRENT ALLOCATIONS AND TARGET APPORTIONMENT FOR HIV TESTING AND TREATMENT SERVICES FOR MARGINALIZED POPULATIONS: CHARACTERIZING PEPFAR INVESTMENT AND STRATEGY IN THE JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. THIS RESEARCH HAS BEEN USED TO EQUIP GLOBAL HIV ADVOCATES WITH IN-DEPTH KNOWLEDGE OF PEPFAR'S INVESTMENT STRATEGY FOR KEY AND MARGINALIZED POPULATIONS. IN 2021 AMFAR STAFF PARTNERED WITH TRANS-LED ORGANIZATION GATE TO DESIGN AND IMPLEMENT RESEARCH ON BEST PRACTICES IN TRANS INCLUSION IN NATIONAL HIV STRATEGIC PLANS (NSPS). THIS WORK INCLUDED GLOBAL RESEARCH ON THE CURRENT LEVELS OF TRANS INCLUSION IN NSPS AS WELL AS LOCAL ADVOCACY IN FIVE TARGET COUNTRIES TO INCREASE TRANS INCLUSION. INTERNATIONAL STAKEHOLDERS FROM UNAIDS AND THE GLOBAL FUND WERE INVOLVED IN PROJECT PLANNING AND HAVE COMMITTED TO USING PROJECT DATA. THE POLICY TEAM ALSO CONTINUES TO PRODUCE USER-FRIENDLY INFOGRAPHICS ON A VARIETY OF GLOBAL HEALTH AND HIV-RELATED TOPICS. IN OCTOBER 2020, AMFAR RELEASED PEPFAR IN THE AGE OF COVID-19: THE NEED FOR SUPPLEMENTAL FUNDING. THIS INFOGRAPHIC SHOWS HOW THE COVID PANDEMIC HAS NECESSITATED COSTLY PROGRAM ADAPTATIONS IN ORDER TO MAINTAIN GLOBAL GAINS AGAINST HIV BY PEPFAR AND THE GLOBAL FUND. AS A RESULT, PEPFAR FACES A $1 BILLION BUDGET SHORTFALL, POTENTIALLY RESULTING IN THOUSANDS OF HIV TREATMENT DISRUPTIONS, NEW INFECTIONS, AND PREVENTABLE AIDS-RELATED DEATHS. IN JUNE 2021, AMFAR RELEASED A NEGLECTED POPULATION: TRANSGENDER INCLUSION IN NATIONAL HIV PLANS, A SERIES OF INFOGRAPHICS THAT SHOW HOW TRANSGENDER PEOPLE ARE OFTEN NEGLECTED, AND SOMETIMES EXCLUDED ALTOGETHER, IN THE KEY SECTIONS OF NSPS. DATA TRANSPARENCY AMFAR MAINTAINS THE PEPFAR MONITORING, EVALUATION, AND REPORTING (MER) DATABASE (MER.AMFAR.ORG). LAUNCHED IN DECEMBER 2018, THE MER DATABASE ENABLES POLICYMAKERS, PUBLIC HEALTH OFFICIALS, ADVOCATES, AND OTHER STAKEHOLDERS TO ACCESS A WIDE RANGE OF PROGRAMMATIC PEPFAR DATA AND INCLUDES DOWNLOADABLE PDFS, MAPS, DATA VISUALIZATIONS, AND DISTRICT-LEVEL DATA. THE DATABASE COMPLEMENTS AMFAR'S PEPFAR DATABASE (COPSDATA.AMFAR.ORG), WHICH HIGHLIGHTS PLANNED FUNDING BY PROGRAM AREA, COUNTRY AND ORGANIZATION FOR EACH YEAR THAT HAS BEEN PUBLICLY RELEASED. THE DATABASE IS DESIGNED TO HELP PEPFAR IN ITS EFFORTS TO INCREASE DATA TRANSPARENCY AND GENERAL PARTICIPATION IN THE PLANNING PROCESS. ADVOCATES FROM AROUND THE WORLD RELY ON THESE RESOURCES TO EASILY ACCESS PEPFAR DATA AND PREPARE FOR ADVOCACY INITIATIVES. AMFAR LAUNCHED THE KEY POPULATIONS AND KEY POPULATION INVESTMENT FUND (KPIF) DATA PROJECT (KPDATA.AMFAR.ORG) IN 2021. THE DATA PROJECT BRINGS TOGETHER AVAILABLE DATA ON KEY POPULATIONS DEMOGRAPHICS, EPIDEMIOLOGY, FUNDING, AND PROGRAMMING FROM UNAIDS, PEPFAR, AND THE GLOBAL FUND. THIS RESOURCE INCLUDES COUNTRY FACTSHEETS SHOWING HOW FUNDING HAS EVOLVED OVER TIME, AND, WHERE POSSIBLE, IDENTIFIES WHO IS RESPONSIBLE FOR IMPLEMENTING KP PROGRAMMING IN THE PEPFAR PROGRAM. THIS PROJECT COMPLEMENTS EXISTING WORK IN THE MER AND COPS DATABASES AND WILL BE A KEY TOOL FOR KP ADVOCATES GOING FORWARD. 11TH IAS CONFERENCE ON HIV SCIENCE AND OTHER CONFERENCES AMFAR'S POLICY OFFICE PARTICIPATED IN THE 11TH IAS CONFERENCE ON HIV SCIENCETHE PREMIER GLOBAL MEETING FOR HIV RESEARCH AND HOW IT MIGHT BE APPLIED TO POLICY AND PRACTICE. DELEGATES CAME TOGETHER VIRTUALLY TO HEAR ABOUT AND DISCUSS THE LATEST HIV RESEARCH FINDINGS AND POLICY ISSUES, AND INTERSECTIONS WITH COVID-19. AT THE CONFERENCE AMFAR STAFF PRESENTED NEW DATA ON THE PEPFAR KEY POPULATIONS INVESTMENT FUND. AMFAR STAFF ALSO CO-AUTHORED A POSTER PRESENTATION SHOWCASING THE USE OF COMMUNITY-LED MONITORING DATA IN SOUTH AFRICA. PUBLIC POLICY DIRECTOR GREG MILLETT DELIVERED A PRESENTATION DURING CROI (CONFERENCE ON RETROVIRUSES AND OPPORTUNISTIC INFECTIONS) REGARDING PREP ACCESS FOR KEY POPULATIONS GLOBALLY. MILLETT ALSO PARTICIPATED IN SEVERAL PLANNING MEETINGS FOR IAPAC'S GLOBAL HIV MEETING THAT CONVENED IN LISBON, PORTUGAL, IN NOVEMBER 2021.
FORM 990, PART VI, SECTION B, LINE 11B	THE FORM 990 WAS PREPARED BY A NATIONALLY RENOWNED ACCOUNTING FIRM IN CONJUNCTION WITH THE ORGANIZATION'S FINANCIAL DEPARTMENT. A COPY OF THE DRAFT FORM 990 WAS CIRCULATED TO THE FULL BOARD OF TRUSTEES FOR DISCUSSION AND COMMENT. EACH BOARD MEMBER WAS PROVIDED AMPLE OPPORTUNITY TO COMMENT ON THE INFORMATION CONTAINED IN THE 990 PRIOR TO ITS FILING WITH THE INTERNAL REVENUE SERVICE.
FORM 990, PART VI, SECTION B, LINE 12C	EACH OFFICER, DIRECTOR, TRUSTEE AND KEY EMPLOYEE OF AMFAR ("FOUNDATION") IS REQUIRED TO ANNUALLY DISCLOSE ANY CONFLICTS OF INTEREST THAT ARISE BY VIRTUE OF EMPLOYMENT, BOARD SERVICE, OR POSITION WITH THE FOUNDATION. THE FOUNDATION MONITORS COMPLIANCE WITH ITS CONFLICT OF INTEREST POLICY THROUGH AN ANNUAL QUESTIONNAIRE/DISCLOSURE STATEMENT THAT IS DISTRIBUTED TO THESE INDIVIDUALS. POTENTIAL CONFLICTS ARE INVESTIGATED IMMEDIATELY.
FORM 990, PART VI, SECTION B, LINE 15	AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. AMFAR'S LAST INDEPENDENT COMPENSATION STUDY WAS CONDUCTED IN AUGUST OF 2020 TO ENSURE THAT THE PRESIDENT & CEO'S COMPENSATION IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AS OF JUNE 2022, AMFAR IS IN THE PROCESS OF REVIEWING ALL EXECUTIVE AND STAFF SALARIES AND HAS COMMISSIONED AN INDEPENDENT THIRD PARTY COMPENSATION CONSULTANT TO PROVIDE AN UPDATED REPORT.
FORM 990, PART VI, SECTION C, LINE 19	AMFAR MAKES ITS FORM 990 AVAILABLE TO THE PUBLIC BY RETAINING A COPY AT ITS PLACE OF BUSINESS AND ON ITS WEBSITE, WWW.AMFAR.ORG. THE FORM 990 IS LIKEWISE PUBLISHED ON THE INTERNET AT WWW.GUIDESTAR.ORG. THE FOUNDATION'S FINANCIAL STATEMENTS ARE MADE AVAILABLE IN ITS ANNUAL REPORT AND ON ITS WEBSITE. THE FOUNDATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE NOT ORDINARILY MADE AVAILABLE TO THE PUBLIC, BUT, IF REQUESTED, WILL BE PROVIDED AT MANAGEMENT'S DISCRETION.
PART IX, LINES 1 & 3	THE FOUNDATION FOR AIDS RESEARCH REPORTS ITS GRANTS NET OF GRANT RETURNS OR RECOVERIES. PERIODICALLY, GRANTS REMITTED TO CHARITABLE ORGANIZATIONS ARE RETURNED TO AMFAR FOR A VARIETY OF REASONS. ON SCHEDULES F & I, GRANTS ARE REPORTED IRRESPECTIVE OF WHETHER THEY WERE ULTIMATELY RETURNED TO AMFAR SINCE CATEGORIZING THE "RETURNED" AMOUNTS WOULD BE TIME CONSUMING. THEREFORE, AMOUNTS REPORTED ON PART IX, LINE 1 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE I; AMOUNTS REPORTED ON PART IX, LINE 3 WILL NOT TIE TO TOTAL GRANTS ON SCHEDULE F.